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 Acute lymphoblastic leukemia (ALL) is the most common cancer of childhood, 
with approximately 2000 cases diagnosed annually in the US. Although cure rates for 
childhood ALL are currently ~80%, T-cell ALL (T-ALL) is still more difficult to treat 
than B-cell ALL, requiring harsher treatments with concomitant harsher side effects. The 
goal of this study was to identify more targeted therapies for treating T-ALL with the 
intent of reducing harsh treatment side effects, thus preserving both lives and long-term 
quality of life.  
 To meet this goal, 26,400 compounds from the ChemBridge library were screened 
utilizing zebrafish larvae since they have the combined attributes of vertebrate 
physiology and small size. The transgenic lck:eGFP zebrafish line with T-cell specific 
GFP was chosen since compounds which eliminate immature T-cells in the thymus might 
also eliminate developmentally arrested leukemic blasts. The screen identified five “hit” 
compounds that cause reduction in GFP without sickening the larvae or causing general 
cell cycle effects. Of these five compounds, one compound, “Lenaldekar” (LDK), was 
effective in killing human Jurkat T-ALL without harming healthy lymphocytes.  
 In vivo, LDK shows efficacy in treating leukemia in both zebrafish and mouse 
xenograft models of T-ALL without observable toxicity or endorgan damage. 
Furthermore, expanded leukemia testing showed that T-ALL, B-ALL, and CML are all 
largely LDK-sensitive, including most treatment-refractory relapsed Ph+ leukemias and 
primary patient samples. Moreover, some AML and multiple myeloma cell lines also 
show LDK sensitivity.  
 Molecular characterization shows that LDK down-regulates the 
PI3K/AKT/mTOR (P/A/mT) pathway, which pathway is up-regulated in ~50% of T-ALL 
cases. Recent results suggest that LDK may achieve this effect via inactivation of the 
insulin-like growth factor 1 receptor (IGF1-R), which activates the P/A/mT pathway. In 
addition, LDK treatment elicits a second activity of G2/M arrest in most sensitive cell 
lines, which arrest appears to be independent of P/A/mT pathway inhibition. 
 Future directions include identifying and modeling LDK’s direct biochemical 
target(s) with the intent of utilizing structure-activity relationships to optimize LDK’s 
chemical structure and efficacy. This study’s ultimate goal is to bring LDK into clinical 
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INTRODUCTION TO T CELL ACUTE  
LYMPHOBLASTIC LEUKEMIA 
Definition of T-ALL 
Acute lymphoblastic leukemia (ALL) is a clinically aggressive disease. It is 
defined as the uncontrolled clonal expansion of an immature lymphocytic precursor cell 
of either the T- or B-cell lineage, which overwhelms the bone marrow, causing cessation 
of normal hematopoiesis in the bone marrow. If left untreated, it is inevitably lethal. T-
ALL (T-cell acute lymphoblastic leukemia) pathogenesis is a multistep process consisting 
of acquisition by a T cell precursor of a series of genetic abnormalities, which disturb its 
normal maturation process, leading to differentiation arrest and uncontrolled 
proliferation. T-ALL is a specific and rare subtype of ALL that arises from a precursor 
cell of the T-cell lineage which becomes developmentally arrested early within certain 
defined stages of intrathymic differentiation.  
T-cell acute lymphoblastic leukemias (T-ALL) and lymphomas (T-LBL) are often 
considered to be the same disease, differing only in burden of the leukemic disease in the 
bone marrow (over 25% of blasts in T-ALL and below 25% in T-LBL). Indeed, 
pathological inspection of blasts from both diseases manifests no difference in cell 
morphology and they are often treated in the same manner in the clinic setting.
1 
However, 
recent findings indicate that some molecular markers differ between T-LBL and T-ALL, 
 
2 
for example BCL2 expression is more elevated in the former.
2
 For diagnostic purposes, 
these two types of T-cell neoplasms can be segregated into two groups: precursor T-cell 
lymphoblastic neoplasms, derived from immature thymocytes, and peripheral T-cell 
lymphomas, arising from T-cells with varying stages of differentiation.
3
  Peripheral T-




T-ALL demographics and statistics 
 
 Each year approximately 6,050  new cases of ALL are diagnosed in the United 
States alone (3,450 male and 2,600 female), of which an estimated 2,400 occur in 
children and adolescents, with an estimated 1440 total deaths from ALL.
5
 This represents 
an incidence of approximately 3 to 4 cases per 100,000 in children ages 0-14 and 1 per 
100,000 for ages 15 and older.
6
 Altogether ALL constitutes 35% of new cancer cases 
diagnosed in childhood as well as almost 75% of all childhood leukemias (ages 0-19), 
making it the most common pediatric malignancy.
7
 Approximately 15% and 25% of new 
ALL cases in children and adults, respectively, are T cell ALL. It is primarily a pediatric 
disease, with diagnoses peaking between 2-5 years of age, but T-ALL can also affect 
adults and exhibits a second incidence peak in the elderly.
5
 In contrast to pediatric 
leukemias, the most common forms of leukemia in the adult population are acute myeloid 
leukemia (AML) and chronic lymphocytic leukemia (CLL).
8,9  
 
 T-ALL occurs primarily as de novo disease and rarely as a secondary neoplasm, 
but it has been correlated to certain genetic and environmental factors. It has a slightly 
higher occurrence in patients with Down syndrome, Bloom syndrome, neurofibromatosis 
type I, and ataxia-telangiectasia. It has also been linked to environmental exposure in 
utero to ionizing radiation, pesticides, and solvents.
10
  In all age groups, there is a slight 
 
3 
predominance of cases among males as well as notable excess incidence among 
Caucasian children.
6
   
 Overall, T-ALL is more difficult to treat and carries a worse prognosis than B-
ALL due to the additional difficulties encountered in T-ALL, such as CNS infiltration as 
well as a worse risk of failure of initial induction therapy. As a result, in recent decades, 
treatment outcome improvements for T-ALL have lagged behind B-ALL. Nevertheless, 
treatment expectations for ALL patients have improved dramatically in recent years due 
to the application of intensified chemotherapy regimens. Consequently, 5-year relapse-
free survival currently is ~80% in pediatric
11




 The poorer outcome in adult T-ALL patients can be attributed to multiple factors, 
including decreased tolerance for intensive chemotherapy regimens, higher incidence of 
poor-prognosis cytogenetics, and lower incidence of favorable subtypes such as the 
t(12;21) translocation.
13,14 
In all groups of patients, relapsed cases of T-ALL still carry a 
dismal prognosis since they often correlate with development of chemoresistance in the 
refractory disease and still constitute a significant clinical problem.
15,16 
  
T-ALL diagnosis and classification 
Patient presentation and symptoms  
 T-ALL usually presents as acute disease. However, in rare cases disease may 
evolve insidiously over several months.
17
 A patient may present with fever caused by 
either the leukemia or by leukemia-induced  secondary infection. Patients may also 
experience fatigue and lethargy caused by anemia, bone and joint pain, and bleeding 
diathesis related to thrombocytopenia. Other symptoms may include loss of appetite and 
 
4 
weight, excessive unexplained bruising, enlarged lymph nodes, pitting edema, petechiae 
due to low platelet levels, and wheezing due to an enlarged thymus (in T-ALL and T-
LBL). Because of similarity of symptoms to many common maladies, T-ALL patients 
may not realize at first that they have a serious disease until it progresses to the point 
where medical attention is mandatory. Furthermore, T-ALL may initially be 
misdiagnosed as asthma due to observed wheezing and because it often can be relieved 
by corticosteroid treatment. 
  
Clinical diagnosis and pathology  
 Due to its acute nature, T-ALL patients usually exhibit large tumor burdens upon 
initial presentation. The examining physician may observe organomegaly, particularly 
mediastinal masses with or without pleural effusions leading to respiratory distress, and 
often infiltration of the central nervous system at the time of diagnosis. Leukemic blasts 
may also spread to lymph nodes or other common extramedullary sites of involvement,  
including lymph nodes, liver, spleen, and meninges. Less commonly, ALL may infiltrate 
orbital tissues, testes, tonsils, and adenoids.  
 Pathological diagnosis includes a complete blood analysis and bone marrow 
smear. Normal bone marrow from a healthy patient will exhibit a mixture of several 
heterogeneous cell types (Figure 1.2A). By contrast, a bone marrow smear from a T-ALL 
patient will show a largely homogeneous cell population of small to medium-sized blasts 
overwhelming the bone marrow (Figure 1.2B). T-ALL blasts are typically cells with 
round to irregular or convoluted nuclei and high mitotic activity. T-ALL blasts also 
usually exhibit expression of nuclear terminal deoxynucleotidyl transferase (TdT). Most 
 
5 
commonly, ALL blasts have scanty cytoplasm, open nuclear chromatin, and sometimes 
presence of nucleoli.  
 Hematological assessment will usually show high numbers of circulating 
lymphoblasts in peripheral blood. Other blood count abnormalities include anemia, 
thrombocytopenia, neutropenia, and leucopenia or leucocytosis with hyperleukocytosis 
(>100 x10
9
/L) present in approximately 15% of the pediatric patients.
17
 Laboratory 
findings may also include elevated serum uric acid and lactose dehydrogenase levels 
because of excessive cell turnover.  
  
T-cell development 
 A discussion on T-ALL leukemogenesis first requires an understanding of T-cell 
ontogeny since many of the molecular mistakes that result in T-ALL arise from this 
normal process gone awry. Normal lymphocyte development takes place in the central 
lymphoid organs:  in the bone-marrow for B-cells and in the thymus for T-cells. The 
thymus provides the microenvironment essential for the development of T-cells from 
common lymphoid progenitors (CLP). When CLPs leave the bone marrow and enter into 
the thymus, they receive signals from the thymic microenvironment, particularly NOTCH 
signaling, engaging them definitively in the T-cell lineage (Figure 1.3).
18
  
 Immature committed lymphocytes, called thymocytes, undergo two crucial steps. 
First, they acquire a unique mature T-cell receptor (TCR) following the rearrangement of 
the genes coding for the different chains of the receptor. Second, they undergo selection 
steps that will retain only thymocytes with a functional receptor able to recognize specific 
antigens presented by thymic epithelial cells via the major histocompatibility complex 
(MHC). If thymocytes receive signals from the functional TCR, they are transmitted to 
 
6 
the nuclei through different signaling proteins, initiating the transcription of survival 
genes (positive selection), while T-cells without a functional TCR die by neglect.
19
 
Toward the end of this maturation process T-cells undergo negative selection, or “clonal 
deletion”, of T-cells with high affinity for self-antigens to avoid self-reactivity.19 During 
this maturation and selection process, T-cells undergo a series of transitions in their 
expression of CD4 and CD8 cell surface markers from double negative (DN,CD4-/CD8-) 
to double positive (DP, CD4+/CD8+), to finally single positive (SP, either CD4+ or 
CD8+) before leaving the thymus (Table 1.2).
20
 
 Thymocyte development is regulated by a series of transcription factors and 
regulators of hematopoiesis such as E2A proteins. Other proteins such as HOX, MYB,  
IKAROS, and especially NOTCH family proteins all play a role in T-cell commitment, 
differentiation, and proliferation. NOTCH proteins also play an important role in self-
renewal of progenitors.
21
 In T-ALL, alterations of these key proteins are common 
findings responsible for leukemic transformation. At the time when rearrangement of the 
different segments, variable (V), diversity (D), and joining (J), of the TCR genes takes 
place, illegitimate recombinations between TCR receptor gene promoter elements and 
genes that are in an open chromatin conformation at this stage of T-cell development, and 
thus susceptible to the recombinase enzyme activity of RAG1/2, can occur. Hence, 
though rare, translocations between TCR and HOX genes or genes coding for proteins 
interacting with E2A are recurrently found in T-ALL and point to the importance of these 








T-ALL subtype classifications 
 Historically, T-ALL and T-NHL were once considered to be the same disease, 
differing only in the degree of bone marrow infiltration (>25% for T-ALL and <25% for 
T-NHL). Indeed, leukemic blasts from both disease classifications are largely 
indistinguishable under the microscope and are treated much the same in many cases. 
However, due to advances in molecular diagnostic and sequencing technologies in recent 
years, it has become apparent that T-cell neoplasms, though relatively rare, are a much 
more heterogeneous group of diseases than previously thought. In addition, Feng et al 
demonstrated that BCL2 is more strongly expressed in T-NHL than in T-ALL.
2
 Likewise, 
differential response to identical therapy regimens in different patients with seemingly 
identical diseases has spurred investigation into the molecular causes of such disparate 
clinical outcomes. It was also anticipated that a more in-depth understanding of the 
molecular mechanisms driving T-ALL could better inform customized treatment regimen 
decisions.  
 Two classification systems have been proposed for T-ALL. The first classification 
system is from the European Group for the Immunological Characterization of 
Leukaemias (EGIL).
22
 Briefly, in the EGIL classification system cellular expression of 
CD3 defines T-ALL. The system further separates T-ALL into four categories depending 
on the maturation status of the cells involved, ie. pro-T, pre-T, cortical-T, and mature T-
cell stages, depending on the expression status of CD markers exhibited by the malignant 
cells (Table 1.3).  
 The second and more recent T-ALL classification system, developed by 
Macintyre et al.,
23
 is based on T-cell receptor (TCR) status (Table 1.4).  It contains 
 
8 
classifications of immature stage (IM), the pre-αß stage, and the TCRαß or TCRγδ 
stages.
24
 Based on actual TRD, TRG, and TRB gene rearrangements, the IM group can be 
further differentiated into the IM0, IMδ, IMγ, or IMβ subtypes. Both of these T-ALL 
stage classification systems are intended to correlate with normal maturation steps 
involved in healthy T-cell development. However, only about half of T-ALL cases 
characterized by them can be assigned to equivalent developmental stages by both 
classification systems simultaneously.
25
    
  
Molecular genetics and translocations 
 Modern advances in chemotherapy regimen intensification, although currently 
successful in curing ~80% of pediatric patients, are not without liability in the form of 
short- and long-term detrimental side effects. Furthermore, 20% of pediatric patients still 
cannot be cured of T-ALL. Clearly novel treatment strategies are needed beyond mere 
chemotherapy intensification and/or hematopoietic stem cell transplant  to improve 
treatment outcomes. These observations as well as advances in molecular diagnosis 
technology have spurred much research in recent years concerning cytogenetic 
abnormalities in T-ALL with the intent of identifying druggable T-ALL-specific 
biochemical targets.  
 Many of the mutations in T-ALL (Summarized in Figure 1.4) can be attributed to 
chromosomal aberrations, which can be observed in ~50% of T-ALL cases by utilizing 
standard karyotyping techniques.
26
 Other cytogenetic abnormalities are far more subtle or 
“cryptic”, requiring FISH (Fluorescence In Situ Hybridization) for detection (Figure 1.5). 
The genetic abnormalities observed in T-ALL may be grouped into four general 
categories as follows (summarized in Table 1.5): 1) Juxtaposition of a T cell receptor 
 
9 
(TCR) promoter or enhancer next to a strong transcription factor, 2) The creation of 
fusion proteins, 3) Deletions and amplifications, and 4) Mutations.  Each of these will be 
discussed in turn. 
 
TCR-transcription factor gene juxtaposition  
 T-cell progenitors rearrange their TCRD, TCRG, TCRB, and TCRA loci, which if 
successful, will lead to expression of a mature TCR. In T-ALL, alterations of these key 
proteins are common findings responsible for leukemic transformation. At the time when 
rearrangement of the different segments (V(D)J) of the TCR genes takes place, 
illegitimate recombinations between TCR receptor genes’ promoter and enhancer 
elements and genes that are active and therefore in an open chromatin conformation at 
this stage of T-cell development can occur. Hence, translocations between TCR and HOX 
genes or genes coding for proteins interacting with E2A are recurrently found in T-
ALL.
19
 Transcription factor genes are the preferred targets of these rare pathogenetic 
chromosomal translocations in the acute T-cell leukemias. Notable examples include the 
bHLH genes MYC, TAL1, and LYL1 which are essential for the development of other 
lineages such as erythroid cells, but with the exception of MYC, they are not normally 
expressed in T-lymphoid cells. Hence, over-expression or mutation of these proteins are 





 The MLL (Mixed Lineage Leukemia) protein methylates histone H3 at lysine 4 
(H3K4) and is the gene most associated with the formation of fusion oncoproteins in T-
ALL.  Under healthy circumstances it regulates gene expression, especially HOX gene 
 
10 
expression, to control skeletal patterning and HSC and early hematopoietic progenitor 
cell development.
28
 Over 40 different balanced chromosomal translocations have been 
identified as fusion partners for MLL in T-ALL, all of which produce a fusion protein 
possessing the NH2-terminus of MLL fused to the COOH-terminus of the fusion 
partner.
27
 The most common MLL-partner fusion genes are listed in Table 1.6. An 8.3KB 
breakpoint cluster region between exons 8 and 13 is the site for most MLL 
rearrangements, which always produce in-frame fusion proteins with fusion partners.
29
 
The SIL-TAL1 fusion is also very common in T-ALL and results from a t(1;14) 
translocation (3% of cases) or from an interstitial deletion of the SIL-TAL locus (~25% 
of cases).
30
 Fusion proteins including ABL1 also occur recurrently in T-ALL, such as 






Genomic deletions and amplifications  
 Often cryptic, genomic deletions and amplifications lead to the loss of tumor 
suppressor genes such as CDKN2A (p14/p16), which encodes a cell cycle regulator. Loss 
of CDKN2A is the most common genetic abnormality in T-ALL and is found in the vast 
majority of patients.
33
 Other deletions may fall upstream or downstream of transcription 
factor genes and thus activate the ectopic expression as in the cases of LMO2 in T-
ALL.
34,35
 Duplications or amplifications of genes in T-ALL may include MYB or the 
amplification of the ABL1 variant fusion gene NUP214-ABL1 on amplified episomes.
31
 
   
Mutations  
 Mutations are commonly found with or without chromosomal abnormalities in T-
ALL. The most commonly mutated gene in T-ALL is NOTCH1, which exhibits 
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activating mutations in over 50% of T-ALL. Mutations in the Notch1 gene occur in the 
homodimerization (HD) and PEST domains, resulting in the constitutive activation of the 
Notch pathway or in an increase of its half-life, respectively. The NOTCH1-associated 
gene, FBXW7, which is responsible for ubiquitinylating NOTCH1 as well as cyclin E1, 
c-Myc, and c-Jun protein, is also often mutated in T-ALL, resulting in lack of 
proteosomal degradation of NOTCH1 protein.
36,37
   
 In addition to these types of aberrations, T-ALL may also exhibit aneuploidy in 
the form of either hyperdiploidy or hypodiploidy. Hyperdiploidy (51-65 chromosomes) 
usually indicates a good prognosis, whereas hypodiploidy (45 or fewer chromosomes) is 
usually accompanied by a worse prognosis (Reviewed in Harrison 2002
38
). 
Unfortunately, with the exception of haploid/diploid status, cytogenetics in T-ALL are 
not as well understood as they are in B-ALL and have not been as informative in risk 
group classification or treatment planning for T-ALL as desired.
39
  
 Despite ~50% occurrence in T-ALL, cytogenetic abnormalities are not entirely 
responsible for all aberrant gene regulation that contributes to T-ALL ontogeny. In fact, 
gene expression analysis has demonstrated that up-regulation of oncogene expression in 
T-ALL can happen in the complete absence of such abnormalities. For instance, the 
Notch1 gene undergoes translocation in less than 1% of T-ALL. This  translocation 
results in lack of the extracellular portion but retains the transmembrane and intracellular 
subunits, resulting in a constitutively active form of intracellular NOTCH1 protein.
40
 
However, gain-of-function mutations in Notch1 have been observed in over 50% of T-
ALL which are not caused by this translocation.
37
 If one includes mutations in Fbxw7, 
 
12 
which is responsible for ubiquitinylating and degrading NOTCH1 protein, mutations in 




Micro RNA contributions  
 More recent investigations indicate that there may be other gene misregulation 
phenomena which may also contribute to T-ALL. For instance, Mavrakis et al. (2011)
43
 
demonstrated that specific micro RNAs (miRNA) targeted towards T-ALL tumor 
suppressor genes were upregulated in T-ALL. Five specific miRNAs with relevance to T-
ALL were identified including MIR19B, MIR20A, MIR26A, MIR92, and MIR223, 
which were predicted to silence T-ALL tumor suppressor genes including IKZF1, PTEN, 
BCL2L11, PHF6, NF1, and FBXW7. 
  
Epigenetic contributions  
 Epigenetic gene misregulation may also play a role in T-ALL development, as has 
been found to apply to other forms of cancer. Abnormal levels of DNA methylation in T-
ALL can result in silencing of WNT pathway elements as well as the cell cycle regulators 
P15INK4B and P16INK4A.
44,45
 Furthermore, in two separate studies, Kraszewska et al. 
(2011)
46
 and Roman-Gomez et al. (2005)
47
 found that DNA methylation status of 
particular genes is different in T-ALL patients, healthy children, and normal thymic cell 
populations. However, it seems that the hypermethylation status of particular genes is not 
as important as assessing the general pattern of methylation of cancer cells, or the CpG 
island methylator phenotype (CIMP status).
48
  
 Both of these studies defined CIMP- status as two or less hypermethylated genes 
and CIMP+ status as three or more hypermethylated genes.  In both studies, strong 
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positive genomic methylation (CIMP+) status correlated with poor outcome, whereas 
lack of high methylation status (CIMP-) correlated with good outcome.  Specifically, in 
the Roman-Gomez et al. study (2005),
47
 relapse rates for CIMP- and CIMP+ were 0% vs 
58%,  mortality rates were 20% and 59%, and 13-year overall survival were 91% and 
17%, respectively. For both studies, 12-year disease-free survival for patients who 
achieved complete remission was significantly different at 100% and 20% for CIMP- and 
CIMP+, respectively. Furthermore, 13-year overall survival was 91% for CIMP- and 17% 
for CIMP+ patients.
49
 However, although these data seem significant, larger high-
powered studies need to be done to confirm these findings. 
Moreover, pre-existing germline mutations in enzymatic processing genes may 
result in pharmacogenetic inhibition of chemotherapeutic drug activity. These germline 
polymorphisms and mutations affect drug metabolizing genes, which may influence 
negatively the response of leukemic blasts to specific chemotherapy agents.
50,51
 Such 
genes may include thiopurine methyltransferase, glutathione S-transferase, cytochrome 
P450 3A4, and methylene-tetrahydrofolate reductase.  All molecular contributors to T-
ALL leukemogenesis are summarized graphically in Figure 1.6. 
 
T-ALL risk level assessment  
 One of the most critical determinations that must be made before treating a patient 
for T-ALL is the relative risk level of the disease. Assessment of the risk category 
ensures that patients with high-risk T-ALL receive treatment of appropriate life-saving 
intensity and that low-risk patients are spared unnecessary toxic effects of treatment.  A 
fine balance must be struck between these two considerations.  
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 Many factors have been found to be contributory to T-ALL relative risk level. The 
first risk factors taken into consideration are patient characteristics, such as age and sex. 
The second set of considerations relate to the T-ALL disease features, such as WBC 
count, immunophenotype, and genetic abnormalities. Additional factors considered are 
the presence or absence of central nervous system (CNS) or testicular involvement, and 
early therapy response as determined in the initial 1-2 weeks of therapy.
17,52 
 
 Within the last 10 years, pediatric T-ALL risk stratification classifications have 
expanded from two classes (standard and high risk) to four classes currently. The prior 
two-class risk stratification system relied only on patient age and WBC at the time of 
diagnosis. Currently the Children’s Oncology Group (COG) defines four classes of T-
ALL risk as low risk, standard risk, high risk, and very high risk.
53
 The estimated 4-year 
event-free survival (EFS) for these groups is 91%, 86%, 76%, and 46%, respectively.
54
 
These groups were defined after examining clinical and cytogenetic data from more than 
6000 patients enrolled on previous studies.   
 However, risk level assessment can be much more complicated due to several 
contributing factors beyond those mentioned above. High risk factors include older age 
(with the exception of infancy), MLL rearrangements, hypodiploidy, CNS involvement, 
drug metabolizing enzyme polymorphisms, hepatosplenomegaly, mediastinal mass, male 
gender, Caucasian race, an immature T-ALL immunophenotype, and hypermethylation of 
tumor suppressor genes. A few of these factors will be discussed further here.  
  
Gene expression profiling  
 With the recent development of microarray platforms for global gene expression 
assessment, it has become possible to assess comprehensively differential T-ALL gene 
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expression patterns. Lugthart et al.
55
 determined in vitro drug sensitivity of ALL cells in 
441 patients. They used a genome-wide approach to identify 45 genes differentially 
expressed in ALL, exhibiting cross-resistance to multiple chemotherapeutic agents. The 
expression of these genes discriminated treatment outcome in two independent patient 
populations, identifying a subset of patients with a markedly inferior outcome. 
Furthermore, Golub et al.
56
 demonstrated the feasibility of using microarrays to 
accurately distinguish subtypes of leukemia using a set of genes as class predictors.  
  
T-ALL treatment regimens 
Once T-ALL has been definitively diagnosed, a course of clinical action is 
chosen. The primary clinical goal of treatment is to achieve a lasting remission, defined 
as the absence of detectable cancer cells in the body and a negative minimal residual 
disease (MRD) reading as determined by FACS. Treatment includes high-dose 
chemotherapy administered both intravenously and intrathecally (IV and IT). 
Chemotherapy regimens typically include three steps: 1) remission induction 2) 
intensification, and 3) maintenance therapy. The purpose of remission induction is to 
rapidly kill most leukemic blasts and achieve an initial remission regardless of non-
debilitating toxicity. This allows the patient to achieve sufficient hematological recovery 
to proceed to further therapy as promptly as possible. CNS prophylactic (or therapeutic, 
in the case of CNS positive disease) chemotherapy is also administered at this point.  
  
Glucocorticoid therapy  
 Glucocorticoids (prednisone/prednisolone and dexamethasone) play a 
fundamental role in the treatment of all lymphoid tumors because of their capacity to 
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induce apoptosis in lymphoid progenitor cells.
57,58 
For this reason, they will be discussed 
more in-depth as an example of T-ALL treatment. The importance of glucocorticoid 
therapy in leukemias and lymphomas is underscored by the strong association of 
glucocorticoid response with prognosis in childhood ALL. Thus, the initial response to 7 
days of glucocorticoid therapy is a strong independent prognostic factor in this 
disease.
59,60 
Resistance to glucocorticoids in vitro is associated with an unfavorable 
prognosis.
61,62 
Moreover, the majority of patients with ALL in relapse show increase 
resistance to glucocorticoid therapy, identifying glucocortocid resistance as a major 
contributor to treatment failure.
61,63 
The glucocorticoids used in T-ALL therapy are 
predisone (or its derivative prednisolone) and dexamethasone. Though structurally very 




 Relative strengths of dexamethasone in comparison to prednisone include a longer 




 and lower IC50 of 
ALL cells in vitro (0.2μM vs 3.5μM).67 Furthermore, treatment regimens which include 
dexamethasone have higher CNS penetration with a concomitant reduction in CNS 
relapse (14.3% vs 25.6%, p=0.017),
68,69
 and are associated with overall better event-free 
survival (81% vs 49%).
70,71
  
However encouraging dexamethasone treatment outcomes may be in comparison 
to those of prednisone treatment, care must still be taken to consider the detrimental side 
effects of dexamethasone use. Prior studies have shown a consistent increase in side 
effects with dexamethasone use over prednisone, including bacterial and fungal 
infections,
72,73 














Tyrosine kinase inhibitors  
 With the recent trend toward more targeted therapies for cancer, tyrosine kinase 
inhibitors (TKIs) have become a useful treatment modality for leukemia. The first TKI to 
be used in treating leukemia was imatinib mesylate (STI-571, brand name Gleevec®), a 
small molecule inhibitor designed to inhibit a small group of tyrosine kinases, including 
BCR-ABL, also referred to as the Philadelphia (Ph+) chromosome.
81
 Imatinib acts as a 
competitive inhibitor for ATP cofactor binding and locks the Abelson kinase portion of 
BCR-ABL in an inactive conformation.
82,83 
Imatinib has been highly successful as 
frontline therapy for treating chronic myeloid leukemia (CML). In CML, imatinib 
induces complete hematologic remission in ~95% of cases, with complete cytogenetic 
responses in ~75% of patients with chronic phase CML.
84
 
   
Philadelphia chromosome-positive B cell ALL  
 Ph+ B-ALL usually carries a poor prognosis even with modern intensive 
chemotherapy regimens. Historically, bone marrow transplant had been recommended for 
children with this subtype of B-ALL, especially those with poor early response to 
induction therapy.
85
 Imatinib also serves as therapy for treating BCR-ABL B-cell ALL 
(Ph+ B-ALL) and has constituted a revolutionary development in treating this disease.
86
 
In Ph+ B-ALL, remission is frequently achieved with imatinib alone.
87
 Unfortunately, 
unlike CML, these responses in Ph+ B-ALL are often transient and in most cases relapse 





Concurrent administration of imatinib with a multiagent regimen in an 
adult cohort led to molecular remission in 54% of patients compared with 19% in those 
who received an alternative chemotherapy regimen.
89
 
   
Imatinib resistance  
 CML in remission, maintained on imatinib, can become treatment resistant over 
time.
90,91 
Imatinib resistance in patients with Ph+ ALL also develops in most cases. A 
common mechanism of resistance is the development of point mutations within the 
kinase binding domain of BCR-ABL, most often in the P-loop or at codon 315 (T315I). 
These mutations can be detected in a small subclone of leukemic cells in 40% of newly 
diagnosed patients. But it becomes the dominant clone in 90% of cases at relapse, thus 
implying selective pressure of the resistant clone after treatment with tyrosine kinase 
inhibitors.
92
 Other mechanisms leading to imatinib resistance in Ph+ B-ALL include gene 




The development of resistance to imatinib in CML and Ph+ B-ALL spawned the 
development of a second generation of tyrosine kinase inhibitors, including dasatinib and 
nilotinib, which are both effective in treating imatinib-resistant ALL with the exception 
of cases harboring the T315I mutation. Dasatinib is a multikinase inhibitor targeting 
several tyrosine kinases, including BCR-ABL and SRC kinases. It is 325 times more 
potent than imatinib, binds to both the active and inactive forms of BCR-ABL, and has 
excellent CNS penetration.
94,95 
Nilotinib is a derivative of imatinib in which modification 






   
Third generation TKIs  
 A third generation of tyrosine kinase inhibitors, including ponatinib, are being 
actively developed, especially to overcome the problematic T315I mutation that confers 
resistance to all existing BCR-ABL-specific tyrosine kinase inhibitors. Though not found 
as often as in cases of B-ALL, ABL1 translocations can also be found in T-ALL in the 
form of NUP214-ABL1 and EML1-ABL1 translocations. TKIs have been found to be 
effective in treating these cases of T-ALL. Dasatinib inhibits NUP214-ABL1 (Nuclear 
pore complex protein 214-V-abl Abelson murine leukemia viral oncogene homolog 1) 
cell proliferation while EML1-ABL1 (Echinoderm microtubule-associated protein-like 1- 
V-abl Abelson murine leukemia viral oncogene homolog 1) cells show sensitivity to 
imatinib.
97
 However, despite encouraging results seen in utilizing second and third-
generation TKIs, it is still likely that these drugs will have to be used in combination with 
other standard chemotherapies, as resistance to single kinase inhibitors is becoming an 




Maintenance therapy  
 The goal of maintenance therapy is to eradicate any residual leukemia cells that 
were not eliminated by remission induction or intensification regimens. Maintenance 
therapy typically includes daily oral intake of mercaptopurine as well as weekly oral 
intake of methotrexate and a monthly injection of IV vincristine and a 5-day course of 
oral corticosteroids. The duration of maintenance therapy is typically 2 years for girls and 







T-ALL relapse therapy  
 Relapsed cases of T-ALL are the most difficult to treat and carry the worst 
prognosis since the disease has already undergone selection for chemoresistance 
characteristics. Overall, ALL relapses occur in 25% of pediatric and 50% of adult cases, 
respectively, with the rate of relapse being correlated with the immunophentotype and 
genetic subtype of the disease.
17,52
 The majority of ALLs relapse in the initial 3 to 5 years 
following initial diagnosis with a small percentage relapsing more than 5 years from 
diagnosis and up to as many as 10 to 20 years later in a small minority of patients.
99
 
 Relapsed ALL may involve the bone marrow or extramedullary tissues, often at 
“sanctuary sites,” such as the CNS, gonads, or both. Statistically, relapses with isolated 
bone marrow involvement seem to correlate with a poorer prognosis than those of 
isolated extramedullary or combined bone marrow and extramedullary relapses.
17
  The 
morphologic and immunophenotypic features of relapsed ALL are often similar to that 
found at initial diagnosis and treatment. However, due to genomic instability coupled 
with drug-induced selection, imunophyenotypic variations may be present at relapse, 
wherein some cell surface antigens present at initial diagnosis may increase or decrease 
in intensity or may have been lost altogether at the time of relapse.
100,101
 
 The primary goal of T-ALL relapse therapy is to obtain a remission and to move 
to allogeneic transplantation as quickly as possible. Allogeneic transplantation must 
proceed quickly since most relapsed patients die shortly after relapsing. One study of 607 
relapsed patients showed a 5-year survival of only 7%. In the same study, transplanted 
patients only experienced 14-16% survival for sibling and unrelated donors, respectively, 
a poignant reminder of how much progress has yet to be made in this field.
102
 In a French 
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study, 44% of relapsed patients achieved a second remission (CR2), but only 12% 
survived.
103
 These statistics clearly indicate a need to focus on optimizing initial therapy 
since salvage therapy in relapsed cases rarely succeeds long-term. These data also 
underscore a need to develop a much better understanding of the molecular mechanisms 
involved in relapsed T-ALL with the intent of using this knowledge to develop better 
targeted T-ALL therapies. 
  
Minimal residual disease (MRD) determination  
 More than 80% of childhood and 35% of adult ALL patients can be cured with 
modern chemotherapy supplemented with HSCT (hematopoietic stem cell transplant) in 
high risk patients.
104
 Still, a substantial number of ALL patients relapse and the 
prediction of relapse with conventional prognostic factors as above  and classical clinical 
risk group assignment is far from optimal.  Mortality rates for relapsed patient cases of 
ALL are a particularly sobering reminder of such treatment limitations. For instance, in 
the FRALLE-93 study, ~80% of patients with induction failures achieved a complete 
second remission utilizing various salvage therapies. However, only 30% were long-term 
survivors, emphasizing the need for early treatment success via complete initial 
elimination of all remaining residual disease.
105
  
 Prior techniques for determination of early induction therapy success relied on 
morphological examination of bone and peripheral blood specimens to detect the 
presence of residual disease. However, the bulk of residual tumor burden is below this 
limit of visual detection. For that reason, molecular techniques for detection of residual 
disease are now available that can detect “submicroscopic disease” not previously 
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identifiable. Techniques are now available that can detect 1 tumor cell in a background of 
10,000 (using FACS) to more than 1 million normal cells (using PCR).  
 Correlation of MRD with treatment outcome has obvious applicability to 
treatment-making decisions in T-ALL. As the treatment side-effects in T-ALL can be 
very harsh, the overriding goal in risk level assessment is to assure that the patient 
receives only as intense a treatment regimen as necessary to eradicate the disease without 
excessive and undue toxicity. Patients who achieve MRD negativity after 2 to 3 weeks of 
remission induction, and therefore have an excellent prognosis, are good candidates for 
treatment de-intensification. At the very least they should not be subjected to further 
treatment intensification.
106,107 
Conversely, MRD determination has the prognostic ability 
to inform treatment decisions when treatment intensification is warranted in resistant 
cases of T-ALL.  Augmentation of subsequent therapy for patients who demonstrate a 
slow early response can significantly improve cure rates as extended induction and 
consolidation are used to deepen morphologic remission.
108,109 
 
Relapsed cases of T-ALL are the most difficult to treat and carry the worst 
prognosis. In such cases, MRD determination can be utilized to herald impending relapse, 
thus accelerating the planning of salvage therapy and/or HSCT. In patients who relapse 
but manage to achieve a second remission, MRD assays can be used to guide the 
selection of optimal post-remission treatment (i.e., chemotherapy versus HSCT). MRD 
measurements can also be used to determine the optimal timing of HSCT. MRD 
measurements post HSCT can also be used to guide the administration of donor 





Detection of MRD can be achieved through utilization of three different 
molecular techniques, including flow-cytometry, PCR detection of leukemia-associated 
fusion genes, and PCR detection of Ig/TCR gene arrangements. PCR detection of Ig/TCR 
gene re-arrangements is the third MRD methodology. Since individual T-cell receptor 
and immunoglobulin genes undergo a unique clonal rearrangement, they can be used as 
specific targets for residual tumor detection.
107
 Although this MRD strategy is the most 
laborious, expensive, and time-consuming, it is reproducible not only within the same 
laboratory but also between different laboratories. Furthermore, it is the most sensitive 
technique. The junctional regions of clonal Ig and TCR gene rearrangements are 
fingerprint-like sequences for each lymphoid malignancy and can be identified in the vast 
majority of ALL patients using the standardized primer sets established through the 
European collaboration within the BIOMED-1 and -2 frameworks.
111,112
 Consensus 
primers can be used to amplify junctional sequences and the length of the product will 
allow discrimination from a background of normal cells. The sensitivity of this approach 
can be as high as 1 cell in 10,000 with sequencing of the initial product and the creation 
of allele-specific primers.
113
 Due to oligoclonality and clonal evolution of Ig/TCR gene 
rearrangements between diagnosis and relapse, it is recommended that at least two 
Ig/TCR targets be followed per patient.
114,115
 
Regardless of the technique used, the following broad conclusions can be made. 
Patients with no detectable MRD at the end of induction have an exceedingly good 
outcome (EFS >90% at 3 years). Those children with a high MRD (>10
-2
) have a poor 





) make up one-third to one-half of all patients depending on the technique used. 
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These patients can be further subdivided based on analysis of a second time point. For 
example, in the study by Coustan-Smith, of 32 patients who were MRD+ by flow 
cytometry at the end of remission induction who then became MRD- at week 14, only 
one relapsed. In comparison, 10 relapses occurred among 18 patients who remained 
MRD+ at the second time point.
116
 It is probable that MRD diagnostics will be included 
in all T-ALL treatment protocols, as MRD data provide so far the most optimal reflection 
of the in vivo response to treatment, which gives the clinician a better knowledge and 
control of the best clinical course of action for individual patients. 
  
Hematopoietic stem cell transplant   
 Hematopoietic stem cell transplant (HSCT) is utilized as a treatment modality of 
last resort for patients who have failed chemotherapy. It is also often used as first-line 
therapy for patients who have high-risk T-ALL that is not expected to respond well to 
chemotherapy. The role of HSCT in treating T-ALL is expected to increase as alternative 
donor sources become available. Alternative donor sources, including cord blood, are 
increasingly used for transplantation in children and adults with leukemia. A higher 
degree of mismatch is acceptable with cord blood units, and outcomes are comparable 
with those of allele-matched transplants.
117,118 
Importantly, cord blood units can be 
obtained with a shorter waiting period and from a larger recipient pool, particularly for 




HSCT is particularly applicable in cases of high-risk T-ALL. High-risk cases 
include those with poor initial response to induction therapy or high MRD, a stem cell-
like immature T-ALL immunophenotype, high WBC count, or a t(4;11) translocation. 
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For example, in a large study of high-risk T-ALL in children comparing chemotherapy 
versus allogeneic HSCT, 5-year disease-free survival was 26.5% vs 56%, respectively.
120
 
Cases of Ph+ B-ALL would also be considered high-risk cases of ALL and eligible for 
first-line HSCT therapy. For instance, in one study of 267 children with Ph+ B-ALL, 5-
year disease-free survival was 25% with chemotherapy alone versus 72% for patients 
receiving HSCT from a matched related donor.
121
 In cases of successful remission 
induction followed by a subsequent relapse, HSCT would also be utilized if a second 
complete response (CR2) could be achieved using intensified salvage combination 
chemotherapy. 
HSCT is usually more successful when using an allele-matched donor (allogeneic 
transplant) in comparison to autologous transplant from the patient’s own bone marrow. 
In the LALA-94 trial, patients with high-risk ALL were allocated to allogeneic bone 
marrow transplantation if they had an HLA identical sibling or were randomized to 
autologous BMT or chemotherapy if they did not. Disease-free survival was 45% in 
patients with a matched donor versus 18% in those without.
122
 A meta-analysis of this 
study and six others encompassing 1,274 patients showed a survival advantage for 
patients with an allogeneic stem cell donor that was augmented in high-risk patients. No 
benefit from autologous BMT was noted.
123
 
An allogeneic transplant seeks to take advantage of the “graft versus leukemia” 
(GVL) effect, wherein if the patient experiences a relapse of T-ALL due to residual 
disease, the graft will recognize the relapsed T-ALL as foreign and destroy it. Allogeneic 
HSCT also carries with it the additional long-term benefit of being able to use T-cells 
harvested from the original donor in an infusion to “boost” the recipient’s engrafted 
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immune system to destroy a refractory T-ALL relapse.
124
  Unfortunately, the GVL effect 
is also often accompanied by “graft versus host disease” (GVHD), in which the 
allogeneic HSCT graft may recognize other healthy recipient tissues as foreign and seek 
to destroy them, resulting in undesirable long-term side effects. However, despite GVHD 
side-effects, many studies have shown that the long-term benefits of using allogeneic 
HSCT are superior to those using autologous transplant. Children undergoing HSCT on 
the average fare better than do adults. The only exceptions are infants who do not show 
benefit from allogeneic HSCT over combination chemotherapy alone. In fact, some 
showed worse outcomes in infants transplanted in first remission even after adjusting for 
presenting clinical features and waiting time to transplantation.
125,126
  
Although many adult T-ALL patients benefit from allogeneic HSCT, still many 
are unable to tolerate the harsh myeloablative (MA) treatments necessary to prepare for 
the transplant, resulting in many cases of treatment-related mortality (TRM). This lack of 
tolerance for the prerequisite myeloablative therapy and consequent TRM increases as 
age increases. In consequence of this observed lack of tolerance for harsh preparative 
MA, many treatment centers are implementing a reduced intensity conditioning (RIC) 
pre-treatment regimen for older patients with T-ALL. The EBMT group has reported on a 
group of 97 patients with adult ALL, including one third of the patients in first CR with 
the majority in higher levels of CR or with refractory or persistent disease. The patients 
received a variety of RIC regimens and, with nearly 3 years of follow-up, the OS for the 
first CR patients was 52%. OS was 27% and 20%, respectively, for patients in 
second/third CR or with a more advanced disease.
127
 Nevertheless, if a patient fails to 
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achieve a complete response after induction or salvage chemotherapy, HSCT is not likely 
to succeed and is not recommended in these cases. 
  
Need for more targeted therapies in treating T-ALL 
Long-term sequelae of T-ALL treatment   
 Thus far, most of the statistics cited in this document have focused on overall and 
disease-free survival in patients treated for T-ALL. However, these statistics do not take 
into consideration the long-term detrimental side effects of treatment for T-ALL. T-ALL 
is typically more difficult to treat than B-ALL, requiring harsher chemotherapy regimens 
with a concomitant increase in undesirable side-effects in both the short- and the long-
term. These effects can be particularly detrimental for children treated for this disease. 
For instance, in comparison to their unaffected siblings, adult survivors of childhood 
cancers are 54 times more likely to have a major joint replacement, 15.1 times more 
likely to have congestive heart failure, and 14.8 times more likely to have a second 
malignancy, to name only a few effects (Table 1.7).  
 Although cure rates for T-ALL have improved dramatically in the past four 
decades, the means by which it has been accomplished has been for the most part 
intensification of the chemotherapy regimens used. Although this improvement in cure 
rates is welcome, such intensive chemotherapy comes at the cost of significant side 
effects, often continuing for years after treatment. And despite recent dramatic statistical 
improvements in cure rates, ~20% of pediatric and >50% of adult cases of T-ALL still 
cannot be cured. So the search for more targeted therapies that treat T-ALL more 




Goals of the dissertation 
 Although T-ALL treatment results have improved dramatically in the last 50 
years, the improvement has come at the cost of increased side-effects of therapy. Hence, 
identification and development of more targeted therapies for treating T-ALL is the 
primary focus for this study. Questions to be asked and goals to be achieved by this study 
include the following: 
 1. Can zebrafish be utilized in an in vivo screen for compounds that show efficacy 
in treating T-ALL? As a vertebrate teleost, zebrafish (Danio rerio) have an immune 
system that is very similar to that of humans, including a thymus in which T-cells 
undergo a maturation process very similar to that of humans. Early zebrafish larvae are 
small enough to fit in a 96-well format, thus facilitating screening of thousands of 
compounds. In addition, transgenic zebrafish are available in which the T-cells have been 
genetically engineered to express eGFP, thus facilitating the observation of drug effects 
on T cell survival as well as T-ALL leukemogenesis and dissemination in vivo.  
 2. Can candidate compounds be identified that are effective in killing T-ALL 
while not exhibiting other toxic side-effects? To this end, candidate compounds identified 
will include those reproducibly exhibiting selective elimination of developing T-cells in 
larval zebrafish thymus while not sickening or killing the larvae. Furthermore, any 
candidate identified from the screen must not exhibit general cell cycle effects, as do 
traditional chemotherapy agents. Candidate compounds must also show lethality toward 
human T-ALL while still demonstrating a sufficient therapeutic window between the IC50 
in human T-ALL cells compared to the IC50 determined for normal healthy peripheral 
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lymphocytes. Candidate compounds will also show efficacy in treating primary T-ALL 
patient samples. 
 3. If compounds can be identified from the screen that exhibit T-ALL specific 
lethality, what is/are the biochemical mechanism(s) of action employed by them? 
Numerous aberrantly activated molecular pathways have been implicated in T-ALL, 
including MAPK, JAK/STAT, NOTCH, Wnt, and PI3K/AKT/mTOR. Any T-ALL 
specific compounds identified in this screen may down-regulate one or more of these 
pathways. In addition, it is also possible that a candidate compound’s activity may reveal 
a novel molecular mechanism heretofore unrecognized for its contribution to T-ALL 
leukemogenesis. In such a case, experiments would need to be designed and executed to 
characterize the biochemical behavior of such a pathway with the intent of identifying all 
druggable targets functioning within it.  
 4. Are the candidate compounds safe and effective in treating T-ALL in vivo? 
Multiple zebrafish models of spontaneous and induced (i.e., c-Myc) T-ALL development 
exist which could be utilized for this purpose. In addition, NOD-SCID mice may be 
utilized in a human xenograft model of T-ALL to determine mammalian response to drug 
candidate treatment. In addition to therapeutic response to treatment, maximum tolerated 
dose will be determined for candidate compounds along with endorgan toxicity and 
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WHO 2008 classification of T-cell neoplasms. 
Adapted from de Leval et al. (2009).
4 
 
Category        Classifications     Subclassifications 
Precursor T-cell  
neoplasms 
 








Leukemic or disseminated T_cell prolymphocytic leukemia 
  T-cell large granular lymphocytic leukemia 
  Adult T-cell lymphoma/leukemia (HTLV1-
positive) 
  Systemic EBV-positive T-cell 
lymphoproliferative disorders of childhood 
   
   
 Extranodal-cutaneous Mycosis fungoides 
  Sezary syndrome 
  Primary cutaneous CD30+ 
lymphoproliferative disorders 
  Primary cutaneous anaplastic large cell 
lymphoma 
  Lymphomatoid papulosis 
  Subcutaneous panniculitis-like T-cell 
lympooma 
  Primary cutaneous gamma-delta T-cell 
lymphoma 
  Primary cutaneous aggressive 
epidermotropic CD8+ cytotoxic T-cell 
lymphoma 
  Primary cutaneous small/medium CD4+ T-
cell lymphoma 
   
 Nodal Angioimmunoblastic T-cell lyumphoma 
(AITL) 
  Anaplastic large cell lymphoma, ALK-
positive 
  Anaplastic large cell lymphoma, ALK-
negative 
  Peripheral T-cell lymphoma, not otherwise 











Stages of T cell development correlate with specific locations in the thymus, distinct 
cell-surface phenotypes, requirements for Notch signals, and TCR rearrangement. 















CMJ +++ Germline Germline 
DN2a CD117hiCD44hiCD25+ 
CD24hiCD27hi 
Cortex + Germline Germline 
DN2b CD117intCD44hiCD25+ 
CD24hiCD27int 
Cortex + DJH Germline 
DN3a CD117−/loCD44−/loCD25+ 
CD24hiCD27−/lo 
SCZ +++ DJH,VDJH Germline 
DN3b CD117−/loCD44−/loCD25int 
CD24hiCD27hi 
SCZ +++ VDJ+ Germline 
DN4 CD117−/loCD44−/loCD25−/lo 
CD24hiCD27hi 
SCZ + VDJ+ Germline 
DP CD4+CD8+TCRβint  Cortex – VDJ+ VJ 
Abbreviations: CMJ, corticomedullary junction; D, diverse; DN, double negative; DP, 
double positive; ETP, early thymic progenitor; H, heavy chain; J, joining; SCZ, 
subcapsular zone; TCR, T cell receptor; V, variable. The single + for Notch signal 
indicates Notch1 receptor expression; however, a specific function or requirement has not 




EGIL classification system for T-ALL 





CD1a CD2 cCD3 sCD3 CD4 CD5 CD7 CD8 CD34 
Pro-T - - + - - - + - + 
Pre-T - + + - - ± - - ± 
Cortical T + + + - + ± + + - 












The TCR system for classifying T-ALL 










-, TCRαß- or TCRγδ- 
Pre-αß  Cytß+, sCD3-, TCRαß- or TCRγδ- 
TCRαß sCD3+, TCRαß+ 




Most frequent genetic abnormalities in T-ALL 
Adapted from Graux (2011).
126 
 
 (Cyto) genetic changes: Genes:  Remarks/prognosis: 
 
 TCR receptor genes translocations (14q11 & 7q34) 
  t(10;14)(q24;q11)  TLX1;TCRA/D  Favorable 
  t(11;14)(p15;q11)  LMO1;TCR 
  t(11;14(p13;q11)  LMO2;TCR 
  t(1;14)(p32;q11)  TAL1;TCR 
  inv(7)(p15q32)  HOXA;TCRB 
  t(7;19)(q34;p13)  LYL1;TCRB 
  t(5;14)(q35;q32)  TLX3;BCL11B  Poor? 
 
 Fusion genes 
  del1(p32) interstitial  SIL-TAL1 
  9(q34) episomes  NUP214-ABL1 
  t(10;11)(p13;q14)  CALM-AF10 
  t(11;19)(q23;p13)  MLL-ENL 
 
 Deletion/amplification 
  del(9)(p21)   CDKN2A 
  del(6q)   Unknown 
  dup(6)(q23)   MYB 
 
 Mutations 
     NOTCH1/FBW7  Very frequent 
        (>80%) 
     JAK1, PTEN, RAS, 

































































Relative long-term side effect risks of adult survivors of childhood cancers 




(N = 10,397) 
%Siblings 
(N = 3034) 
Relative Risk 
(95% CI) 
Major joint replacement 1.61 0.03 54.0 (7.6–386.3) 
Congestive heart failure 1.24 0.10 15.1 (4.8–47.9) 
Second malignant neoplasm 1.24 0.33 14.8 (7.2–30.4) 
Cognitive dysfunction, severe 0.65 0.10 10.5 (2.6–43.0) 
Coronary artery disease 1.11 0.20 10.4 (4.1–25.9) 
Cerebrovascular accident 1.56 0.20 9.3 (4.1–21.2) 
Renal failure or dialysis 0.52 0.07 8.9 (2.2–36.6) 
Hearing loss not corrected by aid 1.96 0.36 6.3 (3.3–11.8) 
Legally blind or loss of an eye 2.92 0.69 5.8 (3.5–9.5) 








Figure 1.1. Five-year pediatric ALL survival rates over the past 60 years. Adapted 






A. Normal healthy bone marrow  B. Bone marrow from a T-ALL patient 
 
Figure 1.2. Comparison of normal and T-ALL leukemic bone marrow. Adapted from 





































Figure 1.3. Stages of haematopoiesis and T‑cell development and T‑cell-leukaemia-
related oncogenes. Bone-marrow haematopoietic stem cells (HSCs) exit the quiescent 
‘niche’ and differentiate to become multipotent progenitors (MPPs). MPPs further 
commit to the lymphoid lineage generating common lymphoid progenitors (CLPs). 
Several progenitor subsets (including MPPs and CLPs) have been suggested to represent 
the progenitor of thymic pro‑T cells. These subsets migrate to the thymus (as early 
T‑cell-lineage progenitors (ETPs) and commit to the T‑cell lineage, progressing through 
the double negative (DN; CD4–CD8–) stages, DN2, DN3 and DN4. Upon successful 
recombination at the T‑cell receptor β (TCRB) locus, pre‑T cells acquire surface 
expression of the pre-TCR that promotes differentiation to the DN4 stage. Pre-TCR-
selected cells reach the double positive (DP; CD4+CD8+) stage, at which point they are 
subjected to the processes of positive and negative selection. Selected cells then exit the 
thymus as single positive (SP) CD4+ or CD8+ T cells. The stages of differentiation at 
which oncogenes that are known to be associated with T‑cell acute lymphoblastic 
leukaemia and required in the bone marrow and thymus are also depicted. LMO2, LIM-











Figure 1.4. Functional classifications of common T-ALL mutations. Molecular 
analysis of T-ALL shows that four major classes of mutations are involved in the 
molecular pathogenesis of T-ALL. These four classes are represented by the four 
diagrams, in which the frequency of each of the different mutations is given. Adapted 







   (A)      (B)             (C) 
 
Figure 1.5. Classical karyotyping and FISH technique. (A) A typical G-banded 
karyotype. (B) Deletion of SIL resulting in SIL-TAL1 fusion gene, demonstrated with the 
SIL-TAL1 DNA probe (DAKOcytomation). The SIL probe (in red) is absent on del(1). 
Adapted from Graux et al. (2006).
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 (C) Multiple colour FISH (MFISH) of a highly 
abnormal metaphase taken from a child with ALL. The colour changes along the 
chromosomes indicate the locations and origins of chromosomal translocations. Adapted 






Figure 1.6. Schematic representation of molecular contributors to T-ALL ontogeny. 











Figure 1.7. Chemical structures of cortisol and synthetic glucocorticoids prednisone, 










ABERRANT SIGNALING PATHWAYS IN T-ALL 
Background 
The last 50 years have seen remarkable progress in success rates for treating T-
ALL. However, this remarkable progress has come about primarily through efforts in the 
clinic to intensify chemotherapy regimens. As a result, detrimental side effects have 
increased concomitantly with long-term remission percentages. Since intensity of 
untargeted chemotherapy intensity has been maximized in T-ALL therapy, further 
progress in treating refractory and relapsed cases must be achieved through alternative 
means. As a result, a primary focus in the field of T-ALL research has been to identify 
and characterize the biochemical pathways that are aberrantly activated  in T-ALL 
leukemogenesis, and to discover mechanisms of resistance to chemotherapy. These 
research endeavors have the principal goal of identifying druggable targets, with the 
expectation that targeted therapy will achieve remission more efficiently and with fewer 
side effects than those observed with traditional chemotherapy. 
Many of the chromosomal translocations and fusion proteins responsible for T-
ALL have been characterized within the last 15 years. However, with rare exceptions 
such as p16 inactivation/deletion, no single chromosomal aberration has been found to be 
dominant in most cases of the disease. As a result, much research has focused on the 
common biochemical pathways downstream of these sporadic cytogenetic abnormalities 
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with the intent of finding common molecular pathways involved in a majority of T-ALL 
cases. 
  
Ikaros’ contribution to T-ALL leukemogenesis 
Ikaros (Ik) is a transcriptional regulator expressed exclusively in the lymphoid 
system that is required for the development of all lymphoid lineages.
1
 Ikaros is a member 
of the Kruppel transcription factor family characterized by the presence of zinc-finger 
domains located at their N- and C- termini. The N-terminal domain is involved in DNA 
binding, whereas the C-terminal domain is important for protein dimerization and 
stability. The Ikaros gene (ZNFN1A1) transcript is processed into a number of isoforms 
due to alternative splicing that regulates the expression of exons coding for the N-
terminal DNA binding domain. Thus, all IKAROS proteins share a common C-terminal 
domain with two zinc-fingers attached to a domain with different combinations of one to 
four N-terminal zinc-fingers, each with distinct DNA binding capabilities and 
specificities. At least three N-terminal zinc-fingers are required for high affinity DNA 
binding to the motif GGGAA/T.
2
  
Only the longer IKAROS isoforms that contain at least three N-terminal zinc 
fingers present high affinity to their specific DNA sequence, whereas the shorter 
IKAROS versions with fewer than three N-terminal zinc fingers cannot bind DNA with 
high affinity. Rather, they behave as dominant negative isoforms upon heterodimerization 
with IKAROS isoforms that have an intact DNA-binding domain.
3
 The shorter, non 
DNA-binding IKAROS isoforms are normally expressed at low levels with respect to 
predominant long isoforms that are abundantly expressed throughout lymphocyte 
development. A mutation that results in the deletion of the N-terminal zinc-finger DNA 
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Aberrant Ikaros function has been correlated with T-ALL leukemogenesis. Mice 
heterozygous for Ikaros mutations at birth show an apparently normal lymphoid cell 
distribution at birth. However, within a few months they develop a very aggressive form 
of lymphoblastic leukemia with a concomitant loss of heterozygosity, resulting in 
predominant synthesis of short IKAROS isoforms.
1,6
 These data demonstrate that 
IKAROS functions as a tumor suppressor in the lymphoid system. In support of this 
model, loss of IKAROS activity has been associated with human leukemia. Loss of 
DNA-binding IKAROS isoforms and/or overexpression of the shorter dominant negative 
form of IKAROS was observed in nearly 100% of childhood and adolescent T-ALL 
cases examined in one study.
7-9
 A current model suggests that the increase in expression 
of dominant negative IKAROS isoforms is a result of alternative splicing and not as a 
result of genomic alterations.  
  
NOTCH1 contribution to T-ALL 
NOTCH1 activity in T-cell hematopoiesis  
 The fundamental components of the NOTCH pathway include the Delta and 
Serrate family of ligands (Delta-like 1, 3, and 4; and Jagged 1 and 2), four distinct 
NOTCH receptors (NOTCH1-4) and the CBF1, Su(H), Lag-1(CSL) DNA-binding 
proteins.
10
 All NOTCH receptors are class I transmembrane glycoproteins expressed at 
the cell surface as heterodimers. They consist of an N-terminal extracellular fragment and 
a C-terminal transmembrane-intracellular subunit.  Of all the NOTCH receptors, only 
NOTCH1 has been found to play a role in T-ALL. The NOTCH1 receptor functions as a 
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ligand-activated transcription factor that directly transduces extracellular signals at the 
cell surface into changes in gene expression in the nucleus.
10
 Activation of NOTCH 
receptors typically occurs via cell-cell contact and interaction of a NOTCH protein with a 
Delta-like or Jagged ligand expressed on the surface of a neighboring cell, typically a 
thymic epithelial cell (TEC) in T-cell ontogeny.  
Two proteolytic events activate intracellular NOTCH1(ICN). First, an 
extracellular metalloprotease, typically ADAM10 or ADAM17, cleaves the receptor in 
the C-terminal portion of the heterodimerization (HD) domain (S2 cleavage). This 
generates a truncated protein with a short extracellular stub that is recognized and 
subsequently processed by the γ-secretase complex (S3 cleavage). Once released from the 
cell membrane, the ICN rapidly translocates to the nucleus, where it forms a 
transcriptional complex with the CSL DNA-binding protein. The ICN-CSL complex  
then activates gene transcription via recruitment of coactivators of the mastermind-like 
(MAML) family, whose transcriptional gene targets include hairy and enhancer of split 1 
(HES1) and c-Myc (Figure 2.1).
11
 
Importantly, transcriptional activation of NOTCH target genes is coupled with an 
active mechanism that ensures the rapid termination of NOTCH signaling. Recruitment 
of RNA polymerase II to the SCL-DNA binding transcription complex triggers 
phosphorylation of the PEST domain of the receptor, and its proteasomal degradation via 
the FBXW7-SCF ubiquitin ligase complex.
10
  
NOTCH plays a critical role in T-cell ontogeny at multiple stages.
12
 T-cell lineage 
specification is dependent on NOTCH, since ablation of NOTCH1 results in a complete 
block at the earliest stages of T-cell lymphopoiesis and lack of specification of the T-cell 
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lineage. Mice harboring a conditional deletion of NOTCH1 fail to develop T-cells and 
show ectopic B-cell development in the thymus. Conversely, mice expressing a 
constitutively active form of NOTCH1 show ectopic T-cell development in the bone 
marrow and fail to produce B lymphocytes.
12
 Furthermore, NOTCH1 plays a role in 
progression through DN1, DN2, and DN3 stages of thymocyte maturation, regulates in 
part TCRB gene rearrangement and β-selection, and regulates the lineage decision 
between αβ and γδ fate.12  
  
NOTCH1 pathway role in T-ALL leukemogenesis 
Aberrant activation of NOTCH1 in T-ALL was first identified in 1991 in rare 
leukemia cases harboring the t(7;9)(q34;q34.3) translocation, which juxtaposes a 
truncated NOTCH1 gene next to the TCRB locus (originally termed the TAN1 
oncogene).
13,14
 Thereafter occasional additional cases of the NOTCH1 translocation were 
found in a small percentage of patients. However, because of the rarity of these 
translocations, the significance of these findings for the pathogenesis of T-ALL remained 
elusive until 2004, when Weng et al.
15
 published a landmark study in which they 
identified activating mutations in NOTCH1, leading to high levels of NOTCH1 signaling 
in over 60% of human T-ALL cases. The most frequent hot spots for mutations in 
NOTCH1 are exons 26 and 27, which encode the N- and C-terminal components of the 
heterodimerization (HD) domains, respectively.
15
 These activating HD mutations are 
found in ~40% of human T-ALL. These HD mutations result in ligand hypersensitivity or 






A second type of NOTCH1 mutation found in 20-25% of T-ALL is found in the 
intracellular PEST (Proline, Glutamate, Serine and Threonine rich) degron domain. The 
loss of the PEST domain results in increased levels of activated NOTCH1 due to 
impaired degradation of the activated receptor by the proteasome.
15,17
 Similarly, 15% of 
T-ALL cases show mutations in FBXW7, which normally ubiquitylates the PEST degron 
domain. Either mutation can result in aberrant accumulation of intracellular NOTCH1 
protein and hence over-activation of target genes’ transcription.17-19 Furthermore, 
FBXW7 is also responsible for ubiquitylating additional oncoproteins such as C-MYC, 
JUN, Cyclin E, and mTOR, for proteosomal degradation. As such, the biological 
consequences of FBXW7 inactivation may be broader than merely those of accumulation 





Gamma-secretase inhibitor treatment of T-ALL 
The high frequency with which activating mutations in NOTCH1 were observed 
initially generated much enthusiasm regarding the therapeutic potential of targeting this 
pathway in T-ALL. Given the requirement of γ-secretase cleavage for NOTCH1 
activation, γ-secretase inhibitors (GSIs), already in use for treatment of Alzheimer’s 
disease, were found to block oncogenic NOTCH1 signaling in T-ALL in vitro. 
5,6,21
 
These results stimulated a phase I clinical trial of GSI MK-0752 for the treatment of 
relapsed T-ALL. However, despite some correlative data showing downreguation of 
NOTCH1 target genes in T-cell lymphoblasts, there were no objective clinical responses, 





Furthermore, many patients showed dose-limiting gastrointestinal toxicities from 
GSI treatment.
22
 These dose-limiting gastrointestinal toxicities were not unexpected since 
inhibition of NOTCH signaling has been shown to induce cell cycle arrest and 
accumulation of mucus-secreting goblet cells in the intestinal epithelium.
23
 However, the 
combination of glucocorticoid treatment with GSIs was much more efficient and 
exhibited a marked protective effect against GSI-induced intestinal toxicity in a mouse 
model of T-ALL, and may suggest that this may be a desirable and effective treatment 




The PI3K/AKT/mTOR pathway in T-ALL 
 Introduction 
 With the disappointing results seen in GSI treatment of T-ALL, research efforts 
turned to determining the reason(s) for T-ALL’s resistance to GSI treatment. In a 
landmark study by Palomero et al. in 2007,
24
 it was discovered that loss of PTEN in T-
ALL conferred resistance to GSIs. Furthermore, it was determined that loss of PTEN 
resulted in upregulation of the PI3K/AKT/mTOR (P/A/mT) pathway, thus effectively 
transferring T-ALL’s oncogene addiction from NOTCH1 to P/A/mT. The P/A/mT 
pathway is known to be upregulated in many forms of cancer, not solely in hematological 
malignancies. Upregulation of this pathway is correlated with poor prognosis in many 
cancers as well as premature aging and resistance to cancer therapy (Figure 2.2).
25
  
PI3K is a heterodimeric protein with an 85KDa regulatory subunit and a 110KDa 
catalytic subunit.
26,27
 Upon activation of a surface receptor tyrosine kinase, PI3K 
phosphorylates membrane phospholipids phosphatidylinositol 4-monophosphate (PIP) 
and phosphatidylinositol 4,5-diphosphate (PIP2) to generate phosphatidylinositol 3,4-
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diphosphate (PIP2) and phosphatidylinositol 3,4,5-triphosphate (PIP3), respectively.
27-29
 
Through its pleckstrin homology (PH) domain, AKT interacts with PIP3, translocates to 
the cell membrane, and undergoes a conformational change that allows phosphorylation 
of AKT at T308 by PDK1, which itself is recruited to the membrane by PIP3 via its PH 
domain.
30,31
 Full activation of AKT also requires phosphorylation at S473 by mTORC2.
32
 
However, mTORC1 is also activated by AKT indirectly by inhibition of the tuberous 
sclerosis complex 2 (TSC2).
33
 Thus, AKT is both upstream and downstream of mTOR. 
Activation of the P/A/mT pathway affects cell survival, growth, proliferation, and 
transformation.
34,35,36
 Negative regulation of P/A/mT activity is mediated by PTEN, a 
phosphatase that removes phosphate groups from PIP2 and PIP3, thus antagonizing 
activity of the P/A/mT pathway.
25
 Each of these molecular entities in the P/A/mT 
pathway will be discussed in turn.  
  
Phosphatidylinositide 3-kinase 
 The phosphatidylinositide 3-kinases (PI3Ks) are a family of lipid kinases that 
catalyze the phosphorylation of phosphotidylinositides at the 3’-hydroxyl group. 
Although three classes make up this family, only Class I PI3Ks have been shown to be 
coupled to extracellular stimuli.
35,37-39
 This class can be subdivided in to Class IA 
kinases, which are activated by receptor-tyrosine kinases (RTKs), and Class IB kinases, 
which are regulated by G-protein-coupled receptors.
40
 To date only Class IA enzymes 
have been clearly implicated in human cancers.
41,42
  
 Class IA PI3Ks are heterodimers consisting of a catalytic subunit (p110) and a 
regulatory subunit (p85). Three isoforms (p110α, p110β, and p110δ) are known for the 
catalytic subunit, which are encoded by the PIK3CA, PIK3CB, and PIK3CD genes, 
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respectively. Seven proteins (p85α, p85β, and p55γ and their splicing variants) comprise 
the regulatory subunits.
40,43
 P85 keeps p110 in a stable but inactive state until, upon 
growth factor stimulation, p110 is recruited to the membrane. p100 is then activated at 
the membrane via the interaction of SH2 domains on p85 and phosphotyrosine motifs on 
the stimulated RTKs. The activated p110 catalytic subunit subsequently phosphorylates 
the D3 hydroxyl position of the inositol ring of PIP2, generating PIP3 at the membrane. 
PIP3 provides docking sites for activation of signaling proteins containing pleckstrin-
homology (PH) domains,
44
 including AKT and PDK1. 
 Activating mutations in the PIK3CA gene, which codes for the specific PI3K 
p110α catalytic subunit, have been found in many forms of cancer, making it one of the 
most frequently mutated oncoproteins in human cancer, along with K-Ras and p53.
45
 
Mutations in PIK3CA cluster in two “hotspot” regions: exon 9 encoding the beginning of 
the helical domain and exon 20 encoding the tail of the kinase domain.
46,47
 The mutations 
found in these two regions of p110α encode single amino acid changes of E542K and 
E545K in the helical domain and H1047R in the kinase domain.
45,48
 The E542K and 
E545K mutations in the helical domain are postulated to affect interactions with 
regulatory proteins, including p85, whereas the H1047R mutation in the kinase domain is 
postulated to affect specificity or affinity of p110α towards its substrates.49 PI3K activity 





Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) 
 PTEN, located on 10q23.3, is a dual lipid and protein phosphatase. Its primary 





 and antagonizing the activity of PI3K.
52
 Incidentally, SHIP-1 can also 
mimic the PIP3 phosphatase function of PTEN but does so by hydrolyzing the 
5’phosphate of PIP3, whereas PTEN hydrolyzes the 3’ phosphate.53 Loss of PTEN 
function results in accumulation of PIP3, mimicking the effect of PI3K activation and 
triggering the activation of its downstream effectors, PDK1 and AKT.
54,55
 
 PTEN is a major tumor suppressor, frequently inactivated in human cancers.
56 
However, PTEN does not fully conform to the formal definition of a tumor suppressor as 
it has been shown to be haploinsufficient in its tumor suppressor function.
57
 PTEN gene 
mutations or deletions are associated with poor prognosis in T-ALL. Two mutations in 
PTEN’s phosphatase domain abrogate tumor suppressor function: C124S abrogates both 
lipid and protein phosphatase activity, while G129E abrogates only lipid phosphatase 
activity.
58
 However, relatively few primary T-ALL patient samples harbor PTEN gene 
mutations (5-27%), and they occur almost exclusively within exon 7.
59
 Likewise, PTEN 
deletions are observed in no more than 9% of T-ALL cases.
59 
 
 These data suggest the existence of other mechanisms whereby PTEN function is 
abrogated in T-ALL, as well as in other types of cancer, which has been verified in recent 
studies. Roman-Gomez et al. showed that PTEN promoter hypermethylation and 
consequent decrease in mRNA expression was reported in ~20% of T-ALL.
60
 NOTCH1 
also transcriptionally inhibits PTEN expression in T-ALL via up-regulation of HES1.
61
 
Furthermore, PTEN can also be regulated by miRNAs, and both miR-19 and miR-21 
have been shown to be T-cell oncogenes by downregulating PTEN in T-ALL.
62,63
  
 PTEN can also be inactivated by several posttranslational mechanisms, including 
phosphorylation, ubiquitination, oxidation, and acetylation.
64
 Specifically, RAK and CK2 
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have been shown to phosphorylate the C-terminus of PTEN and consequently both 
inactivate and stabilize PTEN protein. Thus, it is still entirely possible to have 






 The primary effector of the P/A/mT pathway is AKT (v-AKT thymoma 
retrovirus), also known as protein kinase B (PKB). It was originally discovered as the 
cellular homologue of the transforming retrovirus AKT8 and as a kinase with properties 
similar to protein kinases A and C.
26,28,29,67
 AKT is a serine-threonine protein kinase that 
is expressed as three isoforms—AKT1, AKT2, and AKT3, encoded by the genes PKBα, 
PKBβ, and PKBγ, located at chromosomal loci 14q32, 19q13, and 1q44, respectively.41,68 
AKT1 and AKT2 are the isoforms with the highest expression in thymocytes.
69
 The three 
isoforms share a similar structure. AKT contains an amino-terminal PH domain that 
serves to target the protein to the membrane for activation. Within its central region, AKT 
has a large serine-threonine kinase domain and is flanked on the C-terminus regulatory 
domain by hydrophobic and proline-rich regions.
26,67
  
 AKT is one of the most frequently upregulated kinases in human cancers,
70
 and its 
over-expression is associated with a poor prognosis. AKT regulates cell survival, cell 
cycle progression, migration, proliferation, metabolism, tumor growth, and 
angiogenesis,
71,72
 and as a result, AKT activity is strongly correlated with invasion and 
metastasis.
73
 Furthermore, AKT activation is also found to correlate with resistance to 
chemotherapy and radiation therapy, and conversely, addition of AKT inhibitors to 
antitumor regimens renders cancer cells sensitive to chemotherapy.
74,75
 AKT protects 
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cells from apoptosis by phosphorylation of pro-apoptotic substrates which are 
subsequently sequestered by the chaperone 14-3-3, which then sequesters them away 
from their target sites of action.
76
 In addition, AKT has been shown to regulate HIF-1α 
and VEGF expression, which are both critical mediators of angiogenesis in cancer.
72,77
    
 Aberrant over-activation of AKT can occur by several different mechanisms, 
including amplification, over-expression, mutations in AKT, and/or alterations in AKT 
upstream regulators.
78
 Upstream regulators of AKT activity include cytokines and growth 
factors such as VEGF, FGF, EGF, HGF, IGF and angiopoietin, along with their 
respective RTK cell surface receptors.
79,80
  
 A rare mutation in AKT that increases AKT activity is E17K. Though this 
mutation is seen in only a small percentage of cancers,
81
 it has a significant impact on 
cellular function. The E17K mutation falls in the PH domain of the AKT protein, and 
hence alters the electrostatic interactions of AKT that allows it to form new hydrogen 
bonds with its natural phosphatidylinositol ligands.
81
 This confers many different 
aberrant properties to the AKT protein, including an altered PH domain conformation, 
constitutive activation and constitutive association with the cell membrane. In 
confirmation of these observations, mutated AKT (E17K) has been shown to interact 
with c-Myc to induce leukemia in Eμ-Myc mice.81 AKT can also be over-activated via 
gene amplification, though this phenomenon is not often observed in human cancers.
82,83
 
 Recruitment of AKT by PIP3 to the cell membrane results in a conformational 
change that exposes two crucial residues for phosphorylative activation. Full AKT 
activation requires phosphorylation of both of these two sites in the kinase domain, one in 
the “T-loop” at T308 (phosphorylated by PDK1) and the other in a hydrophobic motif 
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near the COOH terminus at S473.
84,85
 Several kinases have been proposed to 
phosphorylate AKT at the S473 residue, including ILK, PKC, DNA-PK, and ATM. 
However, it is now generally thought that mTORC2 is primarily responsible for 
phosphorylation of AKT at S473 under most circumstances.
86
 In vitro studies have 
established that AKT phosphorylated at only T308 is only 10% as catalytically active as 
AKT phosphoryated at both T308 and S473. Thus, phosphorylation of the hydrophobic 
motif controls both the activity and substrate specificity of AKT.
87,88
 
 After activation at the cell membrane, AKT is able to translocate to the cytoplasm 
and nucleus
28,29,89
 where it phosphorylates a number of downstream targets for regulation 
of various cellular functions (Figure 2.2). So far over 100 AKT substrates have been 
identified,
33
 of which about 40 have been characterized. AKT affects the activity of a 
number of critical transcriptional regulators including FOXO, CREB, E2F, NF-κB, Iκ-K, 
FKHR, HDM2, mTOR and MDM2.
90,91
 These are all either direct or indirect substrates 
of AKT and each can regulate proliferation, survival, and epithelial-to-mesenchymal 
transition.
25
 Besides transcription factors, AKT is able to target a number of other 
molecules to affect the survival state of the cell including BAD and GSK-3β.92 GSK-3β 
regulates β-catenin protein stability. Thus, the P/A/mT pathway is connected to the 
Wnt/β-catenin pathway through GSK-3β. AKT also activates mTORC1 by 
phosphorylating and inactivating PRAS40, an inhibitor of mTORC1 activity.
28,29,93
 AKT 
promotes the G1-S phase transition by blocking FOXO-mediated transcription of the cell-
cycle inhibitor p27Kip1, and/or phosphorylating and inactivating p27Kip1 directly.
90,94
 
 AKT can also be down-regulated by means other than the expected PTEN- or 
SHIP-mediated dephosphoryation and inactivation of PIP3. The tumor suppressors PP2A 
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and PHLPP1/2 are known to inactivate AKT by dephosphorylating residues T308 and 
S473, respectively.
95
 Loss of either PHLPP1 or PHLPP2 results in a striking 30-fold 
increase in the amplitude of AKT phosphorylation after agonist stimulation. There also is 
a striking increase in the duration of AKT phosphorylation after agonist-induced 
activation.
96
 Inactivation of AKT results in G1 arrest since AKT normally phosphorylates 
and inactivates GSK-3β, a kinase that restricts G1 cell cycle progression through 




Mammalian target of rapamycin 
 The mammalian target of rapamycin (mTOR) is a 289KDa serine/threonine 
kinase.
99,100
 It is considered to be a member of the PI3K-kinase-related kinase (PIKK) 
superfamily since its C-terminus has strong homology to the catalytic domain of 
PI3K.
101,102
 mTOR is considered to be a master switch of cellular anabolic and catabolic 
processes since it regulates the rate of cell growth and proliferation via its ability to sense 
mitogen, energy, and nutrient levels.
103,104
 Deregulation of the mTOR pathway is 
frequently observed in cancer as well as diabetes, and as a result, approximately 28% of 
human cancers are expected to be sensitive to mTOR inhibition.
105
  
 mTOR is found in two different signaling complexes: mTORC1 and mTORC2 
(Figure 2.2). In each complex, mTOR is grouped with a different and distinct set of 
signaling proteins that confer upon it a distinct set of functions. mTORC1 consists of 
mTOR, mLST8/GβL, and raptor along with two negative regulatory proteins, PRAS40 
and DEPTOR.
106
 mTORC1’s main functions are to regulate cell growth, proliferation, 
and survival by sensing mitogen, energy, and nutrient signals.
107
 mTORC2 consists of 
mTOR, mLST8, mSin1, rictor, and DEPTOR.
108,109
 mTORC2 regulates the actin 
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cytoskeleton by mediating the phosphorylation state of protein kinase PKCα, and 




 mTOR can be activated by multiple signaling means. It can be activated by 
upstream signals, including growth factors, such as insulin and type I insulin-like growth 
factor (IGF-1), energy, stress, and nutrients.
107
 In response to growth factor ligand 
binding, IGFR is activated and in turn phosphorylates the insulin receptor substrates 1-4 
(IRS1-4) which then trigger multiple downstream signal transduction pathways, such as 
PI3K and hence AKT.
111
 AKT in turn modulates mTOR activity by at least three means. 
First, AKT phosphorylates and inactivates TSC2, which combined with TSC1 antagonize 
mTOR activity through GTP hydrolysis and inactivation of RHEB, which is an mTOR 
activator.
112
 Second, AKT can activate mTOR through phosphorylation and inactivation 
of PRAS40, a negative regulator of mTOR activity.
29
 Lastly, AKT can activate mTOR 




 In mammals, the two best-characterized downstream phosphorylation targets of 
mTOR are p70S6K and 4E-BP1. In mammalian cells, p70S6K is activated by PDK1 via 
phosphorylation at T229.
114,115
 mTOR further activates p70S6K by phosphorylating  
residues S371 and T389.
116,117
 P70S6K is known as the major ribosomal protein S6 
kinase in mammalian cells and is a key player in the control of cell growth and 
proliferation.
118
 Activated p70S6K is suggested to regulate protein synthesis through 
phosphorylation of the 40S ribosomal protein S6, which is postulated to increase the 





 A negative feedback loop from p70S6K to the PI3K pathway has also been 
identified. This inhibition occurs as a result of direct phosphorylation and inactivation of 
IRS by p70S6K,
120,121
 hence down-regulating activity of the PI3K pathway.  
 4E-BP1 is the other well-characterized downstream phosphorylation target of 
mTORC1 and is a repressor of the translation initiation factor eIF4E. Hypo-
phosphorylated 4E-BP1 binds tightly to eIF4E, the mRNA cap-binding protein, and 
represses cap-dependent translation by blocking the binding of eIF4E to eIF4G. In 
response to sufficient growth signals and adequate nutrients, mTOR-mediated 
phosphorylation of 4E-BP1 at multiple sites induces the dissociation of 4E-BP1 from 
eIF4E, allowing eIF4E to bind eIF4G.
122,123
 eIF4G then serves as a scaffolding protein for 
the assembly of other initiation factors including eIF4A, which together recruit the 40S 
ribosome to the 5’ end of the mRNA to commence protein translation.124 
  
The Ras/Raf/MEK/ERK (MAPK) pathway 
 Mitogen-activated protein kinases (MAPK) are a family of evolutionarily 
conserved pro-directed serine-threonine kinases, which play a central role in transducing 
extracellular cues into a variety of intracellular responses including the modulation of cell 
proliferation, differentiation, and apoptosis.
125
 The ERK subfamily is comprised not only 
of the widely studied ERK1 and ERK2, but also the more recently identified ERK5.
126
 In 
normal thymocytes, TCR controls positive selection by modulating ERK activity.
127
 
 There is evidence that ERKs may contribute to T-ALL biology.
128
 Aberrant 
activation of the TAL1 protein by phosphorylation via ERK1 has been described in the 
human T-ALL cell line Jurkat.
129
 Furthermore, activation of ERK1/2 has been observed 
in T-ALL cells on stimulation with IL-7. In contrast, normal T-cells do not appear to 
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activate ERK1/2 in response to IL-7.
130-132
 Ras can also be activated by growth factor 
receptor tyrosine kinases, such as insulin receptor (IR), via intermediates like insulin 
receptor substrate (IRS) proteins that bind growth factor receptor bound protein 2.
132,133
 




 Both Ras and Raf are members of multigene families. There are three Ras 
members (K-, N-, and H-Ras)
132
 and three Raf members (B-, C-, and A-Raf).
134
 Raf is 
responsible for serine/threonine (S/T) phosphorylation of mitogen-activated protein 
kinase kinase-1 (MEK1).
135
 Activated MEK1 then phosphorylates ERK1/2 at specific T 
and Y residues.
136
 Activated ERK1/2 can translocate to the nucleus and phosphorylate 
many downstream phosphorylation substrates, including p90Rsk1, which can activate the 
cAMP-response element binding protein (CREB) transcription factor,
137




 Activating mutations of Ras and Raf occur frequently in both solid and 
hematological malignancies, leading to aberrant activation of their downstream targets 
MEK1/2 and ERK1/2.
141
 Mutations that lead to expression of constitutively active Ras 
proteins have been observed in approximately 20-30% of human cancers.
132
 The majority 
of RAS mutations in humans occur in K-RAS which is followed by N-RAS,
132,142
 making 
K-Ras one of the two most frequently mutated oncogenes observed in cancer along with 
PIK3CA.
143
 It is thought that B-Raf is the most important kinase in the MAPK cascade,
144
 
and the most frequent mutation detected in the BRAF gene is V600E in its activation 
domain.
145
 Often point mutations in RAS genes result in increased Ras activity that 





 mTOR is also activated by mitogenic signals through activation of the 
Ras/Raf/MEK/ERK pathway. Phosphorylation of TSC2 by ERK promotes dissociation of 
the TSC1/2 complex from RHEB and hence attenuates TSC2-mediated inhibition of 
mTOR.
149,150
 Moreover, the MAPK-activated kinase, p90Rsk1 also interacts with and 
phosphorylates TSC2 at a regulatory site leading to inhibition of the tumor suppressor 
function of the TSC1/2 complex and subsequent activation of mTORC1 signaling.
151
 
Furthermore, activated GTP-bound RAS proteins are capable of activating the PI3K 
pathway directly by binding to the p110 catalytic subunit. 
  In cancers bearing mutant RTKs or oncogenes such as RAS that activate both the 
RAF/MAPK and PI3K pathways, blocking the PI3K pathway can actually upregulate 
signaling of the RAF-MAPK pathway because the two pathways have cross-inhibitory 
effects.
152
 RAF-MAPK signaling can in turn drive tumor growth, counteracting the effect 
of the PI3K pathway inhibition, suggesting that rapalogs may also induce activation of 
the MAPK pathway.
153,154
 It was recently shown that mTORC1 inhibition led to the 
activation of  MAPK in a PI3K-dependent manner, providing another example of such 





 The Janus kinase/signal transducer and activator of transcription (JAK/STAT) 
pathway is one more effector of T-ALL leukemogenesis that deserves discussion. It plays 
an important role in biological processes such as apoptosis, differentiation, proliferation 
and cellular immune responses, mediated by growth factors and cytokines.
155
 Binding of 
cytokines results in cell surface receptor oligomerization and activation of the JAK 
family of tyrosine kinases.
156
 Activated JAKs then phosphorylate the cytoplasmic domain 
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of the receptor, thereby creating docking sites for STATs, which are phosphorylated by 




  JAK1 mutations have been observed in 18.4% of adult cases of T-ALL and are 
associated with advanced age at diagnosis, poor response to therapy, and overall poor 
prognosis.
157
 In pediatric T-ALL, the genetic juxtaposition between JAK2 and TEL 
results from the t(9;12)(p24;p13) chromosomal translocation and generates a 
constitutively active TEL-JAK2 protein.
158
 TEL-Jak2 transgenic mice develop fatal 
leukemia, with invasion of non-hematopoietic organs by leukemic T-cells,
158
 further 
supporting the proposition that TEL-Jak2 is an oncogene in vivo. Moreover, the 
expression of a tyrosine-phosphorylated TEL-Jak2 protein correlates with activation of 
STAT1 and STAT5 in leukemic tissues.
158
 STATs are frequently overexpressed and 
hyperactivated by alterations in such upstream signaling pathways, participating in 
oncogenesis through up-regulation of genes encoding apoptosis inhibitors such as Mcl-1 




PI3K/AKT/mTOR pathway inhibitors 
 A primary focus of this study was the impact that a novel small molecule 
inhibitor, Lenaldekar (LDK), has on hematologic malignancies (See Chapter 4). As LDK 
was found to exert this impact in part through modulation of the PI3K/AKT/mTOR 
(P/A/mTOR) pathway, this portion of the thesis will be devoted to addressing P/A/mTOR 






 The first discovered and best characterized mTOR inhibitor is rapamycin 
(sirolimus). It was originally isolated from the bacterium Streptomyces hygroscopicus 
found in a soil sample from Easter Island (also called Rapa Nui in the native tongue). 
Named rapamycin after the island where it was first discovered, it initially showed 
antifungal potential, particularly against Candida albicans.
160
 Rapamycin works by 
binding to FKBP12, an intracellular chaperone. The rapamycin/FKBP12 complex affects 
mTORC1 activity and stability through an allosteric mechanism, binding to a surface of 
mTOR distant from the active site.
161
 In most cellular systems, rapamycin delays cell-
cycle progression through G1 phase arrest, but rarely has cytotoxic effects as a single 
agent, although rapamycin can synergize with chemotherapeutics in some settings.
162,163
 
 Rapamycin was originally utilized as an immunosuppressive agent in organ 
transplant patients. However, its anti-proliferative properties prompted its testing for anti-
neoplastic activity. Because rapamycin is extremely insoluble in aqueous solution, other 
chemical variations of rapamycin have been developed with better pharmaceutical 
properties, including temsirolimus (CCI-779), everolimus (RAD001) and deforolimus 
(AP23573), collectively referred to as “rapalogs.” These rapalogs have been tested 
extensively in clinical trials against various types of cancers. Encouraging results came 
from studies in renal cell carcinoma in which CCI-779 and RAD001 improved overall 
survival among patients with metastatic renal cell carcinoma (RCC)
164
 and hence 
received FDA approval for treatment of RCC. However, rapalogs have failed to show any 





 The existence of feedback loops counteracting the action of rapalogs may be a 
source of rapalog resistance in cancer.
166
 Inhibition of mTORC1 by a rapalog blocks the 
p70S6K-mediated negative feedback loop on IRS-1. This in turn leads to hyperactivation 
of PI3K signaling and increases phosphorylation of AKT at Ser437
166
 as well as 
mTORC2. Because the rapamycin/FKBP12 complex does not bind mTORC2, mTORC2 
was initially thought to be immune from rapamycin effects. However, prolonged 
treatment with rapamycin can decrease mTORC2 activity by disrupting de novo assembly 
of the mTORC2 complex. This disruption happens via sequestration of the intracellular 
pool of mTOR protein in a complex with rapamycin-FKBP12,
167
 although rapamycin-
mediated inhibition of mTORC2 appears to be somewhat cell-type specific.
168
 
 The evidence for rapamycin-resistant mTORC1 and mTORC2 activity has 
prompted the development of pan-mTOR inhibitors that target the ATP binding site of 
the mTOR kinase domain, thus inhibiting both mTOR complexes.
163,169
 Furthermore, as a 
member of the PI3K superfamily of kinases, the kinase domain of mTOR shows strong 
homology to that of PI3K. Hence, the first class of ATP site-competitive mTOR 
inhibitors were found to cross-inhibit PI3Ks as well.
170,171
 Another advantage of pan-
mTOR/PI3K compounds is that they eliminate the feedback activation of PI3K/AKT 
signaling through p70S6K.
172,173
 Preclinical compounds in this “pan PI3K/mTOR” class 
of inhibitors include PI-103, Ku-0063794, Torin-1, and WYE-354.
174
 Originally, despite 
the improved anti-neoplastic activity, global inhibition of mTOR was expected to be 
accompanied by greater toxicity in normal tissues. Yet contradictory to these predictions, 
preclinical studies in a mouse model argue that full inhibition of mTORC1 and mTORC2 







 Activation of the PI3K signaling pathway contributes to cell proliferation, 
survival, and motility as well as to angiogenesis, all of which are responsible for the 
important aspects of tumorigenesis. Considering the impact that hyperactivation of the 
PI3K/AKT pathway exerts on cancer development and resistance to cancer treatment 
modalities, enormous efforts have been undertaken to identify and develop inhibitors that 
down-regulate the activity of this pathway (Table 2.1). Among other effects, inhibition of 
PI3K has been found to suppress angiogenesis and proliferation.
175,176
  
 The PI3K inhibitors wortmannin and LY294002 are commonly used to inhibit 
cancer cell proliferation and tumor growth and to sensitize tumor cells to chemotherapy 
and radiation in vitro. Wortmannin is a natural product isolated from Penicillium 
wortmannin and binds irreversibly to PI3K by covalent modifications. LY294002 is a 
synthetic drug small molecule that reversibly targets PI3K family members. However, 
both wortmannin and LY294002 show little or no selectivity for individual PI3K 
isoforms and have considerable toxicity in animals,
177,178
 and the poor solubility and high 
toxicity of these inhibitors limit their clinical applicability. To overcome these 
shortcomings, derivatives of LY294002 and wortmannin are being developed. PX-866, a 
wortmannin derivative, has more potent and less toxic effects than wortmannin.
179
 In 
addition, LY294002 derivatives TGX115 and TGX126 have been developed and have 




 AKT is a major downstream target of the PI3K pathway and, like PI3K, is known 
to be involved in tumor growth and angiogenesis. Perifosine is the best characterized 
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AKT inhibitor. It is a lipid-based phosphatidylinositol analogue that targets the pleckstrin 
homology domain of AKT that prevents both AKT and PDK1 from binding to PIP3 and 
undergoing membrane translocation and activation.
182
 Perifosine has been shown to 
inhibit the growth of several different solid tumors and has been shown to overcome 
cancer cell resistance to chemotherapeutic drugs and radiation therapy.
75
 Furthermore, 
perifosine induces apoptosis in chemoresistant CCRF-CEM T-ALL cells
183
 and, 
combined with etoposide, induces cell death in a synergistic manner in Jurkat cells.
184
 
Moreover, novel AKT inhibitor A443654 leads to rapid cell death of T-ALL cell lines 
Jurkat, CCRF-CEM, and MOLT-4 as well as primary patient samples.
185
  
 Because of the hyperactivation of AKT via feedback loops from mTOR 
inhibition, dual PI3K/mTOR inhibitors have been synthesized. The first dual 
PI3K/mTOR small molecule to become available was PI-103, a small molecule of the 
pyridofuropyrimidine class.
186
 As PI-103 targets both class IA PI3Ks (at p110α) as well 
as mTOR, it does not lead to AKT activation, which is seen with mTOR-only inhibitors. 
PI-103 possesses strong cytotoxic activity against T-ALL cell lines and lymphoblasts 
derived from T-ALL patients, accompanied by dephosphorylation of AKT and its 
downstream target GSK-3β. Also, mTOR downstream targets, p70S6K and 4E-BP1 are 
dephosphorylated in response to PI-103 treatment.
187
 BEZ235 is another example of a 
dual PI3K/mTOR inhibitor. BEZ235 is an imidazoquinazoline derivative that inhibits 
multiple class I PI3K isoforms and mTOR kinase activity by binding to the ATP binding 
pocket.
188,189 
However, despite extensive development of such P/A/mT pathway 
inhibitors, clinical challenges still exist regarding their usability for treatment of human 
cancers.   
 
75 
 Due to the genetic instability of most human cancers, it can be expected that any 
targeted therapy when used as a single agent will ultimately be overwhelmed by 
resistance development. However, the development of targeted therapies with minimal 
side effects would hopefully enable the combinatorial use of drugs with non-overlapping 
toxicities to effectively treat and eradicate the disease. Furthermore, a single agent with 
dual specificity may have the added advantage of being less likely to induce drug 
resistance than mono-specific agents. Clinical resistance to a kinase inhibitor often arises 
through second-site mutations in the targeted kinase. Targeting two kinases 
simultaneously greatly diminishes the possibility of resistance. Of course, this assumes 
that both kinases are essential for tumor survival and/or growth.  
 However, one necessary precaution with dual inhibitor activity is that the role of 
PI3K and mTOR in a wide range of normal biological processes also means that dual 
PI3K/mTOR inhibitors are also likely to be associated with increased toxicity.
172
 For 
example, in a comparison of the mTOR-kinase only inhibitor PP242 and the dual 
PI3K/mTOR inhibitor PI-103, the latter was found to have a much narrower therapeutic 
range.
174
 Furthermore, early clinical results have found common side effects of these 
inhibitors, including diarrhea, nausea, vomiting, and fatigue, as is already found in 
traditional chemotherapy regimens. Moreover, it is still possible that a tumor could 
develop resistance to even dual PI3K/mTOR inhibition by upregulating the MAPK 
pathway. Thus, combination therapy with both PI3K/mTOR and/or MAPK inhibitors 
may be necessary in some cases, but only to the extent that the combined side effects and 
toxicities of dual treatment are clinically tolerable. Clinicians would also need to know 
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the individual aberrant activation profile of a patient’s tumor sample in order to inform 
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Summary of drugs targeting the PI3K pathway in clinical trials for cancer 




Target Sponsor Phase Cancer type or condition 
PI3K 
inhibitors: 
    
BEZ235 Class I 
PI3K/mTOR 
Novartis Phase I–II Advanced solid tumors; advanced 
breast cancer 
BGT226 Class I PI3K/ 
mTOR 
Novartis Phase I–II Solid tumors; advanced breast cancer; 
Cowden’s syndrome 
BKM120 Class I PI3K  Novartis Phase I  Solid tumors 




Semafore Phase I Advanced solid tumors 




Phase I Advanced solid tumors; metastatic 










Keryx Phase I–II Solid tumors; multiple myeloma; 
ovarian cancer; soft‑tissue sarcoma; 
malignant melanoma 





VioQuest Phase I Haematological malignancies; 
leukaemia; NSC lung cancer 
XL418 AKT and S6K Exelixis Phase I Solid tumors 
mTOR 
inhibitors: 




mTORC1  Wyeth Phase I–II  
 
Approved 
Solid tumors; metastatic breast cancer; 
myeloid leukaemia 









Solid tumors; MM; ovarian and 
endometrial cancer; mantle cell 
lymphoma; brain tumors; NSCLC;  
melanoma 













Solid tumors; HCC; bladder,  head 
and neck cancer; glioma/astrocytoma; 
prostate cancer; brain tumors; gastric, 
breast and pancreatic cancer  
Soft‑tissue and bone sarcomas 
AZD8055 mTORC1 and 
mTORC2 
AstraZeneca Phase I–II Solid tumors; endometrial carcinoma; 
Lymphoma 
mTOR, mammalian target of rapamycin; mTORC1, mTOR complex 1; PI3K, phosphoinositide 3‑kinase; 
S6K1, ribosomal protein S6 kinase 1 (also known as p70S6K). *Information presented is compiled from 
company websites and from www.clinicaltrials.gov and www.fda.gov. ‡The trial has been suspended due 
to low drug exposure. 
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Figure 2.1. Schematic representation of the NOTCH1 signaling pathway and 
transcriptional networks promoting leukemic cell growth downstream of oncogenic 
NOTCH1. The two subunits of the mature NOTCH1 receptor are generated by cleavage 
by a furin protease in the trans-Golgi network soon after translation of NOTCH1 
precursor protein. The extracellular subunit responsible for ligand-receptor interaction 
and the transmembrane subunit responsible for triggering transcription activation interact 
by their respective heterodimerization (HD) domains. Upon binding to its ligands (BD-
like 1, 3, and 4; Jagged 1 and 2B), the transmembrane portion of NOTCH1 is sequentially 
cleaved by ADAM proteases and then by the γ-secretase complex. This final proteolytic 
cleavage liberates the active intracellular fragment of NOTCH1, which translocates to the 
nucleus and activates the expression of target genes by forming a ternary complex with 
the CSL DNA  binding protein and the MAML1 transcriptional coactivator. Small-
molecule inhibitors of the γ-secretase block NOTCH1 activation by retaining the receptor 
at the membrane. NOTCH1 promotes cell growth by transcriptional up-regulation of 
genes involved in anabolic pathways and also by transcriptional up-regulation of MYC. 
In addition, NOTCH1 induces the expression of HES1, a transcriptional repressor that 
promotes the up-regulation of the PI3K-AKT signaling pathway by transcriptional down-
regulation of PTEN. Termination of NOTCH1 signaling is mediated by phosphorylation-























































Figure 2.2. Diagram of key features of the PI3K/AKT/mTOR signaling network. The 
lipid kinase PI3K is activated downstream of oncogenic receptors or intracellular proteins  
in various hematological diseases, with examples shown. PI3K produces second 
messagers phosphatidylinositol-3,4-diphosphate (PIP2) and phosphatidylinositol-3,4,5-
triphosphate (PIP3), which activates PDK1 and Akt.  The mTOR serine-threonine kinase 
is present in two distinct multiprotein complexes, termed mTORC1 and mTORC2. Key 
substrates are shown, and their activities are either increased (pointed arrows) or 










ZEBRAFISH AS A MODEL ORGANISM FOR NORMAL  
AND MALIGNANT HEMATOPOIESIS 
Historical background 
 The zebrafish (Danio rerio) is a small tropical fish, popular in home aquariums, 
that has become a powerful animal model system for understanding the genetic basis of 
vertebrate development. The initial interest in zebrafish as a model system goes back to 
the early 1970s when George Streisinger selected zebrafish larvae to develop the first 
vertebrate assay enabling forward genetic screening.
1
 During the subsequent 20 years, 
zebrafish were almost exclusively used for studying developmental biology and organ 
development in particular. This resulted in the characterization of an exceptionally large 
number of genes involved in vertebrate pathways, which contributed to the establishment 





In more recent decades, the zebrafish has developed into an important model 
organism for biomedical research. Although the main focus of zebrafish research had 
traditionally been on developmental biology, keeping and monitoring zebrafish in the lab 
led to the observation and identification of diseases similar to those in humans, such as 
cancer, which subsequently became a subject for study.
4





based mutagenesis screens in zebrafish were simultaneously performed at the 
Massachusetts General Hospital (Boston, MA) and the Max-Planck Institute (Tübingen, 
Germany), which resulted in the identification of thousands of mutants exhibiting a vast 
array of developmental phenotypes.
3,5 
Since then, the zebrafish has increasingly become a 
model of human disease, since mutants have been found with mutations in the orthologs 
of human disease genes. 
 Zebrafish have contributed to hematologic research for more than 50 years. 
Interest in zebrafish embryology dates to the 1930s,
6
 and they have long been used for 
zoology and toxicology research.
7
 However, their developmental hematology only 
entered the literature in 1963 with the second appearance of zebrafish in the journal 
Nature, as a representative teleost fish with an intraembryonic origin for blood.
8
 Then the 
first descriptions of zebrafish blood cell morphology appeared in the 1970s.
9-11
 The 
modern phase of zebrafish hematology research, driven by genetic experimental 
approaches, started just over 10 years ago with the collection of zebrafish mutants with 




Zebrafish disease model strengths 
 Zebrafish exhibit a number of characteristics that make it an exceptionally strong 
model organism for scientific research. Their small size (<5 cm as adults) means that 
more zebrafish can be housed in a smaller space and with far less maintenance expense 
than other mammalian models, such as mice. Furthermore, zebrafish have high fecundity, 
with a single mating pair producing up to 100 transparent eggs twice per week. 
Thereafter fertilization and embryogenesis take place ex vivo, thus facilitating in vitro 





Embryos remain translucent for several days, allowing unprecedented visualization of the 
development and function of somatic systems. Moreover, cells can be tracked either with 
specific probes using whole mount in situ (WISH) in fixed embryos, or followed in 
realtime in live transgenic fish in which fluorochromes have been used to tag cells.  
 The zebrafish is a vertebrate with complex organs and represents a blueprint for 
all vertebrate organogenesis. Rapid organogenesis is a strength of zebrafish as an 
experimental organism with most organs becoming fully functional within 3-5 days post-
fertilization (dpf). This rapid organogenesis coupled with transparent embryos for several 
days after fertilization make the zebrafish uniquely qualified among experimental 
organisms for studies in vertebrate organ development and function (Figure 3.1A).
15,16
 
 The zebrafish genome is also sequenced with multiple genetic markers and gene 
chips are already available commercially. For these reasons, large zebrafish screens can 
be carried out speedily and at relatively low cost to dissect the molecular basis of 
developmental pathways as well as the phenotypic analysis of embryogenesis and 
organogenesis in vivo.  
 The zebrafish is amenable to forward genetic screens on a scale that is not feasible 
in any other vertebrate models.
17
 There is a high degree of genetic conservation between 
man and other vertebrates despite millions of years of divergent evolution.
18-19
 
Invertebrate models are generally unable to recapitulate the pathogenesis of many human 
diseases. By contrast, the zebrafish system allows forward genetic approaches in a 
vertebrate that can manifest the pathologies of human diseases. In addition, the 
establishment of transgenic lines expressing fluorochromes, such as green fluorescent 
protein (GFP), in specific developing tissues,
20,21





zebrafish particularly amenable to in vivo studies of neoplastic progression, metastasis, 
and remission.   
 Zebrafish are also highly amenable to reverse genetic studies (reviewed in Refs. 
22,23). Key reverse genetic techniques for functionally studying genes of interest in 
zebrafish include transient gene over-expression and knockdown, stable transgenesis,
24
 
and recovering stable mutated alleles by the TILLING method (Targeting Induced Local 
Lesions in Genomes).
25




 Because fertilization and development occur ex utero in zebrafish, alternative 
chemical means may be used to phenocopy the impact of mutagenesis, but within a much 
shorter and less expensive experimental timeframe. For instance, antisense morpholinos 
are routinely used to knock down target protein expression in zebrafish embryos by 
micro-injection at the one-cell stage. Antisense morpholinos block either mRNA splicing 
or translation, both of which lead to loss of expression of the targeted gene. Morpholino-
mediated knock down is transient,
27
 lasting for only up to 3-4 days.
28
 However, due to 
rapid organogenesis, this is often sufficient time to phenocopy mutants with mutations in 
the corresponding target genes during early development.
29
           
  
Transgenic zebrafish generation via ZFN, TILLING and TALEN mutagenesis 
 The development of zebrafish models that accurately phenocopy human 
congenital diseases requires the generation of tailor-made mutations in the orthologs of 
human disease genes. Targeted knockout approaches and the engineering of genes 
carrying predetermined mutations has been very successful in mice, but are not feasible 





recovering mutations in a gene of interest has been the introduction of TILLING 
(Targeted Induced Local Lesions IN Genomes) methodology.
30-32
 This reverse genetics 
strategy utilizes the screening of chemically mutagenized genomes by resequencing and 
TILLING to identify mutations in specific genes. More recently, zinc-finger nuclease 
(ZFN) technology has been developed that offers the possibility to engineer mutations in 
specific zebrafish genes.
33,34
 The technique employs zinc-finger nucleases, chimeric 
molecules consisting of a DNA binding zinc-finger domain and the FokI restriction 
endonuclease, to induce targeted mutations in any gene of interest. This technique offers 
the possibility of a rational and straightforward strategy to engineer precise models of 
human inherited diseases in zebrafish. 
 Alternatively, a more recent technology has emerged, referred to as “TALEN” 
(Transcription Activator-Like Effector Nuclease). TALENs, which comprise an 
engineered array of transcription activator-like effector repeats fused to the nonspecific 
FokI cleavage domain, introduce targeted double-stranded breaks in human cells at 
specific targeted DNA sequences with high efficiency. Repair of these double-stranded 
breaks by normal DNA repair mechanisms, such as nonhomologous end-joining or 




 The same TALEN technology has recently been applied to zebrafish embryos via 
microinjection of TALEN constructs at the one-cell stage. This has resulted in the 
efficient introduction of small insertions or deletions (indels) at cleavage sites in 
endogenous zebrafish genes. These indels frequently result in frameshift knockout 





to use both ZFNs and TALENs should enable any researcher to rapidly and easily create 
targeted mutations in any zebrafish gene of interest.
36,37
 
 In zebrafish, the application of chemical genetics to dissect biological processes 
has also become an attractive alternative to mutagenesis screens due to its technical 
simplicity, inexpensive reagents, and low startup costs. It also offers a new approach in 
that it is reversible and adjustable, allowing dosing adjustments to be made. In a zebrafish 
chemical genetic screen, small molecule inhibitors may be added directly to fish water in 
a 48- or 96-well format and used to block a specific protein function (Figure 3.1B). In 
vertebrates, only fish and amphibians are amenable to chemical genetic screens carried 




Zebrafish disease model limitations 
 One of the more obvious zebrafish disease model limitations is the lack of a 
respiratory system as found in mammals. Hence, diseases of the mammalian respiratory 
system cannot be recapitulated in zebrafish. Another limitation of the zebrafish system is 
that the blood-brain barrier of the larval zebrafish is not fully formed until 10dpf. 
Therefore, the assessment of CNS-mediated effects in larvae may erroneously identify 
compounds that are excluded from the brain in older fish and in mammals. Furthermore, 
the larval zebrafish is a rapidly-developing system, which may not be appropriate for 
modeling the effects of compounds on adults.
40
 
 The zebrafish also lacks an extended history of disease model experimentation. 
Unlike many mammalian models that have been used for decades, the zebrafish cannot 





limitations. Lack of antibodies to surface proteins and difficulty of establishing cell 




Zebrafish cancer models 
 
 Throughout its research history, zebrafish have mostly been used for 
developmental studies. However, while keeping zebrafish in the laboratory environment, 
researchers noticed different diseases developing in adult fish, including cancer. Human 
disease models for drug efficacy screening have also been developed in zebrafish across a 
wide range of disease areas, including cardiovascular disease, infection, inflammation 
and metabolic diseases.
42
 Studies on zebrafish cancer revealed that zebrafish 
spontaneously develop many types of tumors.
43-46
 This led to enthusiasm that the 
development of zebrafish cancer models could enable researchers to exploit them to 
conduct modifier screens. Such modifier screens could combine the ability to model 





Zebrafish oncogenesis induction 
 Because zebrafish in the wild develop cancer relatively infrequently, researchers 
sought to accelerate the tumorigenesis process through various means. There are three 
principal ways that cancer can be experimentally induced in zebrafish: (i) carcinogen 
treatment; (ii) transgenesis; and (iii) genetic predisposition achieved by induced 
mutations or insertions.
47
 Researchers have appreciated the relative ease of treating fish 





animals can be exposed for longer time periods.
48,49
 Historically, fish had already been 
used as a model for toxicological and carcinogenesis assays.
50,51
  
 While it is difficult to document the extent of spontaneous fish tumorigenesis in 
the wild, upon exposure to aqueous carcinogen treatments they can develop a wide range 
of benign and malignant tumors. Interestingly, many of these fish cancers histologically 
resemble human tumors, suggesting the conservation of genetic mechanisms underlying 
the pathogenic changes associated with malignancy.
52-54
 In support of this, fish have 
many orthologs of the oncogenes and tumor suppressor genes that have been identified in 
mouse and humans, including multiple Myc, Ras, and Notch family members, β-catenin, 
p53, Mdm2, Bcl-2, and Bcl-xL. Strong amino acid similarities and functional studies 
suggest the conservation of these proteins with their mammalian counterparts.
55-57
 Of 
note also is the fact that teleosts, including zebrafish, lack ARF, which in mammals 





 The largest number of studies on cancer development in zebrafish at this point 
come from transgenic zebrafish expressing mammalian oncogenes. This approach takes 
advantage of the ability to inject foreign DNA into one-cell-stage zebrafish embryos.
4
 
Generating stable transgenic zebrafish is efficiently done with Tol2 transposons.
59
 
Because constitutive expression of a transgenic mammalian oncogene often results in 
lethality before achieving sexual maturity, several approaches, such as the cre-loxP and 








 Fluorescence was also very elegantly used for tracking recombination events in 
cre/lox-regulated systems in whole fish. In a zebrafish model of T-ALL, a floxed dsRED 
gene between the rag2 promoter and EGFP-mMyc transgene resulted in dsRED 
expression in thymocytes. Directed activation of CRE recombination resulted in a switch 





 Despite the availability of technology to generate cancer-prone transgenic 
zebrafish, cancer remains a disease that requires the simultaneous loss or mutation of 
multiple genes in the same cell. For this reason, transgenic cancer zebrafish lines still 
require time to accumulate additional mutations or a “boost” of carcinogen treatment in 
order to generate sufficient numbers of cancer-bearing fish to be experimentally useful 
and statistically meaningful. For instance, a nonsense mutation in zebrafish Apc was 
found to result in less than 30% of heterozygous fish spontaneously developing liver and 
intestinal tumors from 15 months of age onward. However, treatment of Apc 
heterozygotes with 7,12-dimethylbenz [a]anthracene enhanced tumorigenesis, resulting in 
intestinal, hepatic, and pancreatic tumors, with frequencies 3- to 4-fold higher at 6-12 
months of age than treated wild-types. Furthermore, the tumors displayed activated Wnt 





 Different groups have also experimented with direct transplantation of 
mammalian cancer cells into zebrafish embryos. This creates an in vivo system in which 





zebrafish embryos in which development can be followed in real time.
65
 This 
visualization advantage is further enhanced in part by the development of a zebrafish line 
that lacks all types of pigmentation named “casper.”66 However, the visualization of 
fluorescently-tagged proteins and cells can still often be very much feasible even without 
abolition of pigment due to the relatively small size of zebrafish adults, depending on 
what anatomical site and at what developmental stage the animal is visualized.
65,67
  
 For instance, in another elegant study, researchers used i.p. injection to introduce 
fluorescently labeled human breast cancer cells into 1-month-old zebrafish. They used the 
transplanted cells in combination with three-dimensional modeling to show how the 
human cells interact with vessels and invade in tissues. The experiment showed that 
expression of vascular endothelial growth factor induces openings in vessel walls that can 




Zebrafish as a model for human hematopoiesis 
  
 The primary purpose of this work was to use the zebrafish as an experimental 
organism to identify and characterize novel compounds with potential for targeted 
efficacy in treating human T-cell acute lymphoblastic leukemia (T-ALL). In order for 
such a purpose to be achieved, a large degree of structural, genetic and functional 
homology must exist between human and zebrafish in their respective hematopoietic 
systems in order for findings in the zebrafish model to be translatable to human T-ALL. 
The organization of the genome and the genetic pathways controlling signal transduction 
and hematopoietic development appear to be highly conserved between zebrafish and 
humans.
19





zebrafish can be exploited to elucidate human hematopoietic mechanisms, both healthy 
and malignant, as well as treatment modalities with the potential to address them. 
 Although the first circulating blood cells are visible by 24 hours postfertilization 
(hpf) during zebrafish development, the processes required for hematopoietic stem cell 
(HSC) generation are already underway from 5hpf, when gastrulation takes place. During 
the gastrula period, embryos develop three germ layers – ectoderm, mesoderm and 
endoderm. Among these three germ layers, blood and angioblasts (endothelial 




Primitive and definitive hematopoiesis 
 As in other vertebrates, there are two major waves of hematopoiesis in zebrafish 
(Figure 3.2). The first wave, primitive hematopoiesis, originates in the yolk sac in 
mammals and birds, and in the intermediate cell mass (ICM) in zebrafish, specifically the 
anterior lateral plate mesoderm (ALM) and the posterior lateral plate mesoderm (PLM). 
At early somitogenesis stages, the ALM gives rise to a transient hemangioblast 
population that differentiates into myeloid and endothelial cells. In its turn, the PLM 
gives rise to a second population of hemangioblasts that differentiate into erythroid and 
endothelial cells.
71,72
 Red blood cells do not differentiate in the PLM. Instead the 
erythroid derivatives of the PLM migrate to the midline to differentiate in the 
intermediate cell mass.
73
 However, this primitive wave is only transient, and the 
successive definitive wave starts intraembryonically. 
 The second wave of hematopoiesis, definitive hematopoiesis, initiates in the 
zebrafish embryo from 30hpf. This wave gives rise to hematopoietic stem cells (HSCs), 





including erythroid (erythrocyte), myeloid (macrophage, neutrophil, monocyte) and 
lymphoid cells (B and T).
74
 HSCs can also reconstitute hematopoietic lineages in clinical 
or experimental settings when transplanted into a host lacking HSCs. Apart from 
megakaryocytes and natural killer (NK) cells, all other differentiated blood lineages have 
been found and characterized in zebrafish embryos and/or adults, and they exhibit a high 




 In vertebrate embryos, the first definitive HSCs arise primarily from the aorta-
gonad-mesonephros (AGM) region and express runx1 and c-myb transcription 
factors.
76,77
 From 48hpf, these c-myb+ cells appear in the posterior part of the embryo, 
known as the caudal hematopoietic tissue (CHT).
78, 79
 The structure of the CHT highly 
resembles that of kidney marrow and fetal liver, its equivalent in mammals, as it has 
many sinusoids that slow down the blood flow, and this could help seeding of HSCs.
79
 
The c-myb+ cells later appear in the thymus from 3dpf and in the pronephros from 4dpf.
2
 
 In the adult zebrafish, the kidney serves as the main hematopoietic organ,
80
 and its 
function is equivalent to that of the bone marrow in mammals. T cell progenitors develop 
initially within the kidney marrow and then migrate to the thymus where they undergo 
differentiation.
81
 Kidney marrow generates adult hematopoietic cells throughout the life 
of a zebrafish. The development of T cells and the thymus in zebrafish is remarkably 
similar to that of mammals with the main exception that the zebrafish thymus remains as 










Zebrafish and human hematopoiesis homology 
 However, despite differences in physiological location of the hematopoietic niche, 
the gene programs utilized in each tissue are well conserved across species.
83
 A high 
degree of conservation in transcription factors and the sequence of their functional 
domains translate into a high degree of functional conservation. As in mammals, the 
basic helix-loop-helix transcription factor tal1(scl) and its partner lmo2 sit at the apex of 
hematopoietic and endothelial development.
84-86
  Gata1 and spi1(pu.1) have conserved 
lineage-specific erythroid and myeloid fate-specifying roles.
87
 Runx1 and cmyb retain 
their connection with definitive hematopoiesis.
77,88
 Detailed analyses of the staggered 
temporal expression of hematopoietic transcription factors imply a conserved regulatory 
hierarchy.
86,89
 Probing the transcriptional regulation of hematopoiesis in zebrafish is 
hence informative for mammalian hematopoiesis. Furthermore, zebrafish have proven to 
be a useful heterologous model for examining human disease-associated transcription 
factor mutations and their fusion proteins.
77,90
 
 Zebrafish T cell-specific developmental genes have also been cloned and show 
strong homologies to mammalian counterparts with similar expression and functional 
profiles. They include ikaros, lck, GATA-3 rag-1, and rag-2.
91-93
 Intracellular cytokine 





 and SOCS negative regulators.
101-103
 Descriptive and 
functional data point to their involvement in cytokine and growth factor signaling 
pathways mediating conserved biologic responses.
95,104
 Furthermore, zebrafish possess all 
the major proteins of the coagulation system, including both vitamin K-dependent 







 Despite the similarities between zebrafish and human hematopoiesis, differences 
between them do exist which must be considered before undertaking experimental 
conception and design. While the antibody-based, adaptive immune system is present in 
all jawed vertebrates (gnathostomes),
106
 zebrafish differ considerably with regard to the 
presence of major lymphoid tissues.
91,107
 Bone marrow, gut-associated lymphoid nodules 
(Peyer’s patches), and primitive lymph nodes are absent from zebrafish.  In the absence 
of lymph nodes, antigen-presenting cells (APCs) and lymphocytes interact in the only 
truly secondary lymphoid organ of zebrafish – the spleen, a site where dendritic cells 
(DCs) reside.
108
 The liver and gut can also serve as surrogate lymphoid organs.
109
  
 There are also significant differences in immunoglobulin gene organization, gene 
usage, and gene number of immunoglobulin genes.
110
 Furthermore, zebrafish express a 
new immunoglobulin heavy chain subtype, immunoglobulin Z, which does not have a 
counterpart in mammals.
111
 Moreover, immunoglobulin isotype class switching is a 
process that has its earliest evolutionary roots in amphibians and therefore does not occur 
in fishes.
91,112
 Additional limitations of the zebrafish model in hematology research are 




Zebrafish as a model for human leukemia 
 
 Malignant hematologic diseases, including acute leukemia and myelodysplastic 
and myeloproliferative disorders, have been modeled in zebrafish, which recapitulate 
many features found in analogous human leukemias (Table 3.2).
114
 The development of 
lymphoblastic leukemia zebrafish models was facilitated by the early availability of 
lymphocyte-specific promoters, such as rag2, providing appropriately selective 







transgenic zebrafish were generated by injecting cDNA constructs into embryos at the 
one-cell stage, resulting in the tissue-specific expression of the oncogene when integrated 
into the genome. 
  
Zebrafish models of T-ALL 
 The first zebrafish model of T-ALL involved expression of the mouse Myc gene 
tagged with eGFP under control of the rag2 promoter.
116
 The stable transgenic rag2-
EGFP-mMyc zebrafish lines developed T-cell leukemia with a mean latency of 22 days 
post-fertilization (dpf) and a mean survival of 82 dpf.
39
 At the molecular level, mMyc-
induced leukemias are similar to a subtype of human T-ALL expressing both scl and 
lmo2. In human patients, this subgroup represents the most common and most treatment-
resistant form of this disease.
117
 Furthermore, combining bcl2 over-expression with the 
enforced Myc expression generated a transplantable leukemia with increased resistance to 
γ-irradiation-induced apoptosis.118 
 However, though effective in generating a visible form of T-ALL in zebrafish, the 
induction of leukemia in this model was so efficient that the majority of the injected 
animals died before reaching sexual maturity, thus hampering the ability to maintain a 
stable line.
54
 To solve this problem, a conditional Cre-loxP system was subsequently 
introduced in the form of double transgenics expressing rag2:loxP-dsred-loxPGFP-MYC 
and heat-shock-inducible Cre recombinase (hsp70:cre). In this model, T-cell 
lymphoblastic lymphoma was efficiently induced after heat-shock induction and T-cell 
lymphoblastic leukemia (T-LBL) rapidly progressed to T-ALL.
55
 Establishing inducible 
T-ALL models allows tumor-prone transgenic lines to be propagated disease-free and to 









 The second T-ALL model was created by introducing the human T-ALL 
oncogene, Notch1, into zebrafish under control of the rag2 promoter, fused to eGFP for 
easy visualization of T-cells. Transgenic animals begin to show expansion of 
fluorescence in the thymic region at about 5 months of age with progression to 
widespread dissemination similar to that seen in the mMyc model. Similar to that seen in 
the rag2:EGFP-mMyc model, crossing rag2:Notch1 model animals to a rag2-Bcl2-
expressing fish leads to a significant decrease in disease latency.
118,119
 
 More recently, Gutierrez et al. (2011)
120
 sought to generate a model in which Myc 
activity could be modulated in established tumor cells. To this end, they generated stable 
transgenic zebrafish expressing rag2:Myc-ER. In this model the zebrafish rag2 promoter 
drives expression of a fusion transgene consisting of human MYC fused to the ligand-
binding domain of a modified estrogen receptor. This modified estrogen receptor is post-
translationally induced by 4-hydroxytamoxifen (4HT) treatment but not by endogenous 
estrogens.
120
 In this manner, they generated a conditional zebrafish model of T-ALL in 
which 4HT treatment induces MYC activation and disease, and withdrawal of 4HT 
results in T-ALL apoptosis and tumor regression.
120 
 
 To characterize a heritable predisposition to T-ALL, Frazer et al. (2009)
121
 
pioneered a phenotype-driven forward-genetic screen in zebrafish. Using transgenic WIK 
fish with T-lymphocyte-specific expression of eGFP (WIK lck:eGFP),
121
 they performed 
chemical ENU mutagenesis, screened animals for GFP+ tumors, and identified multiple 





zebrafish lines of heritable T-cell malignancy. Two are reported as having dominant 
inheritance: shrek (srk) and hulk (hlk), and the third exhibits recessive inheritance: oscar 
the grouch (otg). Each line faithfully recapitulates human T-ALL and T-cell 
lymphoblastic lymphoma (T-LBL) in onset, invasion pattern, and morphology. 




Zebrafish models of B-cell acute lymphoblastic leukemia (B-ALL) 
 
 The only current zebrafish model of B-ALL is a transgenic fish expressing the 
ETV6-RUNX1(TEL-AML1) fusion oncogene. This oncogene is associated with t(12;21) 
pediatric B-cell acute lymphoblastic leukemia, but does not result in ALL when driven 
from the rag2 promoter. However, when expressed ubiquitously, an ALL-like disease 
with the phenotypic features of B-ALL is observed at low levels of penetrance.
122
 Gene 





Zebrafish models of acute myeloid leukemia (AML) 
 Myeloid leukemia has also been modeled in zebrafish. The AML1-ETO (AE) 
translocation (also known as RUNX1-RUNX1T1) is the most common chromosomal 
translocation in acute myeloid leukemia. However, as in earlier T-ALL models, 
ubiquitous over-expression of the oncogenic AE protein in zebrafish embryos leads to 











Zebrafish utility in drug screening 
 In addition to its power in forward genetic screens, the zebrafish is now emerging 
as a new model for drug discovery.
31
 The high degree of sequence structure conservation 
between the proteins of zebrafish and humans increases the likelihood that bioactive 
compounds recovered in zebrafish chemical screens will retain activity and specificity for 
preclinical studies in mice and eventually for clinical studies in humans. In recent years, 
zebrafish have been used for evaluating the toxicity of pharmaceutical agents.
125
 In 
zebrafish larvae, an in vivo toxicology assessment has the advantage that it can be 
achieved in a week, a much shorter time frame than that required when performing 
comparable mammalian assays. In addition, much larger numbers of compounds can be 
tested in zebrafish than what can be feasibly tested in mice. 
 The potential of zebrafish to be used as a vertebrate model for chemical screens 
was first assessed by Peterson and colleagues.
126
 They used wild-type zebrafish embryos 
to screen for chemical modifiers of development using a strategy analogous to genetic 
screens, where mutations are identified that affect development of different organ 
systems. In their screen, 1,100 synthetic small molecules were randomly chosen from the 
DIVERSet library (ChemBridge Corp.) and added to the embryos. The effects of the 
individual compounds on the embryos’ morphology and physiology were examined 
visually under the dissection microscope. From this screen, 2% of the compounds cause 
lethality, and 1% caused specific phenotypes leading to the identification of compounds 
that affect development of the central nervous system, the cardiovascular system, 





 Many of the advantages of utilizing zebrafish in compound screening stem from 
its small size (5cm for an adult and 5mm for 7dpf larvae), combined with high fecundity, 
which enable medium-to high-throughput screening. Small size also means that only 
milligrams of compound are needed for screening in 96-well plates as the larvae can live 
in as little as 50μL of fluid. Both of these factors contribute to relatively low costs for 
high-throughput zebrafish screening. Furthermore, zebrafish fertilization and embryonic 
development are external and rapid, with most organ systems becoming functional within 
3-5 dpf when the larvae are still small enough to grow in 96-well format. At that age, the 
zebrafish larvae are not fetal but are closer to the juvenile state in that the nervous system 
is mature, vital organs are functioning and tissue architecture is fully developed at the 
time of the assays. Rapid development in vitro also means that small molecule 
compounds can be added with precise timing, allowing pinpointing of the exact temporal 
requirement for the target protein.
126
 
 Another very important advantage in zebrafish drug screening is the fact that the 
zebrafish larvae are whole vertebrate organisms with many of the same organ systems as 
humans and other mammals, including a cardiovascular system, immune system, and 
kidneys, relevant to human biology and physiology. Screening large panels of chemical 
compounds for specific effects in cell culture is a well-established strategy for drug 
discovery. However, many biological processes cannot be reproduced in cultured cells 
and often the three-dimensional environment of cells determines their function. 
Moreover, metabolism of the compounds may be profoundly different in whole 





vitro cell-based chemical screens would fail to identify drugs that require metabolic 
activation within an organism. 
 Furthermore, “hit” compounds have to be cell-permeable, devoid of obvious 
toxicities, effective, and possess favorable pharmacodynamic and pharmacokinetic 
profiles. Drug discovery in the whole organism, therefore, combines screening and 
animal testing in one step. While slower than in vitro assessment, compared with cell-
based drug screening, a whole-animal model substantially reduces the likelihood of 
encountering common issues that arise during late stages of drug development, such as 
drug toxicity and off-target side effects. This is particularly relevant in testing potential 
new chemotherapeutic agents, where toxicity often limits efficacy.
127
 Therefore, one 
would like to screen large numbers of small molecule compounds with high throughput 
for biological activity in whole organisms as early in the screening process as possible. 
This now has become feasible using zebrafish embryos. Until recently zebrafish has 
remained the only vertebrate model used for large-scale chemical screens. However, 
Xenopus exhibits many of the same desirable drug screening traits as zebrafish and is 
now being used in some drug screening applications (Table 3.3).
34
 
 Finally, chemical screening is facilitated by the fact that zebrafish are reasonably 
tolerant to dimethylsulphoxide (DMSO), generally used in such screening efforts. 
Compounds of chemical libraries are usually stored as stock solutions in DMSO, which 
also serves as a vehicle to improve solubility of the compounds in the aqueous solutions 
used to culture embryos.
128
 Zebrafish embryos are surprisingly tolerant to a range of 
DMSO concentrations.
129,130
 A final concentration of 1% DMSO is compatible with 





range of concentrations in embryos and larvae. High tolerability for DMSO also enables 
matrix pooling in compound screening where multiple compounds are aliquoted into a 
single test well with larvae, thus greatly accelerating throughput.
131,132
 The strategy is, 
however, primarily suitable for synthetic, combinatorial libraries as many compounds 
will have no biological activity. In contrast, pooling of compounds from collected 
bioactive libraries is undesirable as this leads to a very high rate of toxicity.
133 
  
Lack of need for known molecular target 
 Conventional in vitro drug screens often focus on identifying specific inhibitors of 
an established molecular target. For example, imatinib (Gleevec®) was designed to target 
the ABL kinase, blocking signal transduction pathways downstream of the BCR-ABL 
fusion kinase in chronic myeloid leukemias.
31
 By contrast, reversion of a disease 
phenotype in the zebrafish does not require the a priori knowledge of gene targets. This 
allows the identification of drugs that disrupt novel pathways or affect the interactions of 
complex molecular signaling cascades that can contribute to disease states.
134
 
Furthermore, zebrafish drug screens can be used to establish a rapid and reliable readout 
for novel drug compounds’ impact in vivo. Taken together, chemical zebrafish screens 
promise to provide a rapid, alternative approach to identify lead compounds for diseases 
whose underlying biology and pathological mechanisms are not well understood. 
 Further therapeutic development to optimize for specificity will, however, benefit 
from identification of the molecular targets and understanding of the mode of action of 
the recovered lead compounds.
30
 The use of tagged compounds (i.e., biotin tag) facilitates 
identification of their molecular targets.
135
 However, a drawback of the tagged library is 
that the tag may block biological activity of the compound.
135





screens suggests that tagging the compounds leads to a dramatic reduction in the number 
of compounds that are biologically active. In a screen of untagged compounds, ~3% 
induced a phenotype
126
 vs. 0.07% (1 out of 1536) of the same compounds with a tag.
135
 
Moreover, the untagged compounds were biologically active at low concentrations 
(~1μM),126 while a relatively high concentration of the tagged compounds was required 
to induce a phenotype (50μM).135 Moreover, once identified, candidate molecular targets 
should be confirmed and validated by independent means such as by morpholino-
mediated knock down of the target, or, if available, by detailed analysis of a mutant with 
a mutation in the target gene. 
  
Use of genetically modified zebrafish for drug screening 
 One promising use of drug screens in the zebrafish is to employ genetically 
modified zebrafish embryos. Mutants from either the phenotype-driven forward 
mutagenesis screen or from reverse genetic TILLING may be used as well as transgenic 
fish (over-) expressing a gene of interest. Over the last few years, several zebrafish 
mutants have been isolated that mimic human disease, such as polycystic kidney disease, 
heart disease, and anemias.
23,34,136
 These genetically modified fish may be screened with 
large panels of drugs for reversion of the phenotype. Mutants in disease genes that 
display an embryonic phenotype, as well as transgenic lines with an embryonic 
phenotype may be used for these drug screens. The targets of the chemical compounds 
will include factors downstream of the mutant gene and may include an (over-) expressed 
transgene as well. These types of screens provide a direct means to screen for chemical 
compounds that act in disease pathways.
137





process in a whole, vertebrate organism would represent potential lead compounds for 
drug development. 
 The feasibility of this approach was first demonstrated by the identification of a 
novel class of compounds capable of suppressing the gridlock mutation.
138
 Gridlock 
mutants have a hypomorphic mutation in the hey2 gene, a hairy/enhancer of split-related 
basic helix-loop-helix transcription factor, leading to the malformation of the dorsal aorta 
preventing blood circulation to the trunk and tail.
139
 Coarctation of the aorta is a common 
human congenital cardiovascular malformation that is morphologically similar to the 
gridlock mutant.
140
 After screening a diverse library of 5,000 drug-like compounds, two 
structurally related compounds were identified that completely rescued gridlock mutants 
in a dose-dependent manner to develop a normal vasculature without causing additional 
developmental defects.
138
 The mechanism of action is unknown, but the more potent 
compound, GS4012, induced expression of vascular endothelial growth factor (VEGF). 
In support of this notion, over-expression of VEGF is sufficient to rescue the gridlock 





Forward chemical genetic screens 
 One of the first forward chemical genetic screens was aimed at identifying new 
pathways modulating definitive hematopoietic stem cell formation during zebrafish 
embryogenesis.
141
 In this screen, North et al. found that prostaglandin E2 (PGE2) 
increased HSC number. PGE2 interacts with the Wnt signaling pathway to regulate HSCs 
through cAMPPKA-mediated β-catenin phosphorylation.142 A stable derivative of PGE2 





bone marrow, strongly suggesting a therapeutic potential.
141
 As another prostaglandin-
relevant example, Yeh and colleagues utilized the transgenic hsp70:AML1-ETO (AE) 
zebrafish line and screened for compounds that suppressed the inducible erythropoiesis-
to-granulopoiesis conversion.
143
 They found that chemicals that inhibit PGE2 or β-
catenin pathways block the capacity of AEs to redirect hematopoiesis, a strategy that 
could potentially provide therapeutic benefits in AML patients. These two independent 
screens collectively demonstrate the crucial roles of PGE2 and β-catenin interaction in 
normal and leukemic hematopoiesis.  
 In another example of a chemical suppressor screen in zebrafish, Stern and 
colleagues screened a chemical library using the recessive cell cycle mutant crash & burn 
(crb), a homozygous lethal mutation of the bmyb gene that has an increased number of 
mitotic cells as detected by pH3 antibody staining.
132
 Screening of a 16,320-compound 
library resulted in the identification of one compound, named persynthamide, which 
suppressed the phenotype of the crb mutant. Because of its ability to suppress a specific 
cell cycle defect in crb mutants without affecting wild-type embryos, persynthamide 




 In summary, the zebrafish as a model organism for scientific research offers a 
unique combination of opportunity and convenience unequalled currently by any other 
experimental organism. Because of its small size and fecundity, its maintenance is less 
expensive than other mammalian models such as mice. Furthermore, ex vivo development 
of transparent eggs and embryos combined with rapid organogenesis offer a very 





vertebrate, its physiology and genome exhibit a high degree of homology with that of 
humans such that many human diseases can be recapitulated in the zebrafish model. This 
also means that any remedy found for such a disease in zebrafish is likely to translate to 
having a similar remedial impact in human patients with the same disease.  
 The primary purpose of this work was to use a transgenic lck:eGFP zebrafish to 
screen for and characterize novel compounds with the ability to eliminate immature T-
cell progenitors developing in the thymus, and thus also eliminate immature, 
developmentally-arrested leukemic blasts. The zebrafish offers unique opportunities for 
conducting such a large-scale drug screen due to the ease of creating transgenic reporter 
animals, small size and rapid development, along with an immune system which is 
remarkably similar to that of humans, including the ability to develop leukemia. 
Furthermore, a zebrafish in vivo drug screening platform also provides the context of an 
entire vertebrate organism capable of simultaneously testing for efficacy, bioavailability, 
and lack of systemic toxicity in the same screening. For these reasons, it is likely that the 
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Limitations of the zebrafish model in hematology research 






Problem Possible solution(s) 
Anatomy Different morphology of blood cells, eg, 
erythrocytes and thrombocytes are 
nucleated 
Abstraction in experimental design, ie, seeing 
similarity rather than difference and learning 
from difference 
 Different gross anatomy, eg, what is the 
equivalent of the marrow stroma? 
Improving depth of understanding of zebrafish 
physiology and anatomy will likely narrow 
rather than widen the apparent gaps 
Physiology Lack of cell markers/antibodies Partially addressed by rapidly expanding 
toolbox of fluorescently labeled cell 
compartments, but generation of a repertoire 
of zebrafish antibodies is highly desirable 
 Lack of hematopoietic cell lines Not currently addressed 
 Lack of in vitro differentiation system 
(hematopoietic cell culture assays) 
Identification and purification of zebrafish 
hematopoietic growth factors with 
optimization of zebrafish cell culture 
techniques 
 Lack of inbred strains, eg, for 
transplantation studies; to facilitate gene 
mapping 
Limited attempts to generate inbred lines 
which retain hybrid vigor 
Genetics Genetic divergence between fish and 
humans 
Completion of zebrafish genome sequencing 
project will provide more information about 
missing genes, but some genetic diseases will 
prove difficult to model due to genome 
duplication and divergent evolution 
  Despite divergence in gene structure and 
function, zebrafish bioassays for human gene 
activity can still have validity 
 No technique for targeted gene 
modification by homologous 
recombination 
TILLING (Targeting Induced Local Lesions 
In Genomes) allows  off the shelf  ordering of 
mutants in any gene of interest 
  Library of characterized insertional mutants; 
random retroviral insertions disrupt the 
function of genes and tag the insertion site 
within the genome 
  Transient knockdown of any gene easily 
achieved using morpholino antisense 
oligonucleotides (stable mutant line is 
preferable because of the possibility of 
nonspecific/off target morpholino effects) 
 Limited options for conditional 
transgenesis or gene modification 
Temperature sensitive alleles hsp70 (heat 
shock) promoter Gal4-UAS transgenic 






Zebrafish models of human leukemia 
Adapted from Carradice and Lieschke (2008)
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Disease  Zebrafish model  Model type  Phenotype  
T cell leukemia  Mouse Myc 
overexpression  




Leukemia and tissue 
tumours  











regulation via ENU 
mutagenesis 
Spontaneous leukemogenesis 
with variable penetration 
T-cell leukemia and tissue 
infiltration 
Acute myeloid 






using mRNA injection  
Early maturation block, 



















Increase in gata1 



























 Summary of chemical library screens performed in zebrafish and Xenopus 
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Figure 3.1 Zebrafish larva at 3-7dpf. (A) Organs such as the heart are clearly visible 
due to the optical clarity of the larva at this age. (B) Zebrafish larvae at 7dpf in a 96-well 








Figure 3.2. The ontogeny of hematopoiesis in zebrafish. Hematopoiesis in zebrafish 
occurs in consecutive waves. Embryonic primitive hematopoiesis (yellow) starts at 
around 11 hours post fertilization (hpf) when hemangioblasts (which have the potential to 
become either endothelial vascular cells or hematopoietic cells, shown in white) appear in 
the anterior lateral mesoderm (ALM) and posterior lateral mesoderm (PLM), which 
collectively are analogous to the blood islands in the mammalian yolk sac. 
Hemangioblasts in the PLM later converge medially to form the intermediate cell mass 
(ICM; not shown), where primitive erythrocytes (red) predominantly arise. The ALM, 
which later becomes the rostral blood island (RBI; not shown), is the major site for 
primitive myeloid cells (blue). At around 24 hpf, embryonic erythrocytes enter 
circulation. As circulation begins, hematopoiesis within the ICM gradually diminishes. A 
transient definitive wave (pink) initiates shortly after multi-lineage erythromyeloid 
progenitors appear in the posterior blood island (PBI). Starting from 26 hpf, definitive 
HSCs (gray) emerge from hemogenic endothelial cells of the dorsal aorta in the aorta-
gonad-mesonephros (AGM) region. Shortly thereafter, HSCs migrate to and seed the 
caudal hematopoietic tissue at 48 hpf, which is an expansion of the PBI and acts as a 
transient hematopoietic site that gives rise to erythroid, myeloid and thromboid (yellow) 
cells. The caudal hematopoietic tissue is equivalent to mouse fetal liver or placenta. 
HSCs from the AGM region colonize kidney around 48 hpf. Kidney marrow, which is 
functionally similar to mammalian bone marrow, gives rise to all blood lineages, 
including erythroid, myeloid, thromboid and lymphoid (green) cells for the larval and 
adult zebrafish. At around 54 hpf, common lymphoid progenitor (CLP) cells from the 
AGM region seed the thymus, which is the site for maturation of lymphoid T cells. 







ZEBRAFISH SCREEN IDENTIFIES NOVEL COMPOUND WITH  
SELECTIVE TOXICITY AGAINST LEUKEMIA 
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Summary and perspectives 
 Within the last 50 years, great progress has been made towards curing ALL, with 
cure rates rising from single digits to currently ~80% for children and ~50% for adults.
1
 
However, this progress has come with a dear price since it has come in the form of 
intensification of applied chemotherapy regimens.
2
 Such treatment intensification carries 
with it a concomitant increase in detrimental side effects for both the short- and long-
term. Among other side effects, adult survivors of childhood cancer treatment, in 
comparison to their untreated siblings, are 54 times more likely to have a major joint 
failure and replacement, 15 times more likely to have congestive heart failure, 14.8 times 
more likely to have a second primary cancer, and 10 times more likely to have severe 
cognitive dysfunction, to name only a few detrimental long-term side-effects (See 
Chapter 1, Table 1.7).
3
 
 There is, therefore, clearly a great need for improvement in treating childhood 
cancers, and ALL is the most common form of childhood cancer. For a clinical course of 
treatment to be considered to be “successful,” clearly more must be taken into 
consideration than merely 5-year Kaplan-Meier statistical survival rates. Not only 
survival, but overall long-term quality of life must be the final clinical and research goal 




be cured currently even with these improvements.
1
 Moreover, these statistics are slightly 
worse when considering T-ALL cases alone, which fare worse overall than B-ALL 
cases.
4
   
  The primary objective for this study was to identify such novel compounds as 
may have the desired combined traits of effectively eliminating T-ALL blasts while not 
causing significant harm to collateral healthy tissues. This objective appears to have been 
met with the identification of the novel compound Lenaldekar (LDK), which shows 
efficacy in treating human T-ALL both in vitro and in vivo without observable toxicity or 
endorgan damage to model organisms. Furthermore, LDK does not exhibit general cell-
cycle effects as do traditional chemotherapy regimens. Moreover, LDK shows a one-log 
difference in the IC50 sensitivities of leukemic blasts in comparison to healthy circulating 
lymphocytes, thus exhibiting a useful therapeutic window for treatment. An additional 
unexpected benefit from this study was that LDK shows efficacy in treating most types of 
leukemia, including glucocorticoid-resistant T-ALL as well as treatment-refractory 
relapsed B-ALL and CML.   
 A followup goal after identifying such novel targeted therapeutic compounds was 
to characterize the molecular mechanism of action of the identified compound(s). 
Because LDK’s efficacy was not dependent on the presence or absence of PTEN, it was 
deemed unlikely that it acted through down-regulation of the NOTCH1 pathway. Instead 
LDK shows down-regulation of the PI3K/AKT/mTOR (P/A/mT) pathway upon 
treatment, as exhibited by de-phosphorylation of AKT, mTOR, and p70S6 Kinase. Based 
on recent results, it seems possible that LDK may achieve this effect via binding and 




the P/A/mT pathway. In addition to down-regulation of the P/A/mT pathway, LDK also 
exhibits a second, independent effect of G2/M block in most sensitive cell lines. The 
mechanism of action of the G2/M block is currently undergoing investigation.  
 An additional goal of the thesis was to determine whether or not the zebrafish 
could be a feasible model organism for conducting such a drug screening. Indeed, the 
zebrafish proved to be an excellent model organism for this study. As a vertebrate teleost, 
it shows significant molecular and anatomical homology to the human immune system.
5
 
Furthermore, at 5dpf, zebrafish already have fairly well-developed organ systems, 
including a thymus with visible developing T-cells.
6
 Simultaneously, 5dpf larvae are still 
small enough to fit comfortably within the 96-well test plate format, thus saving both 
space and money. In addition, the starting hypothesis that compounds which selectively 
eliminate immature T-cells developing in the zebrafish thymus might also eliminate 
developmentally-arrested human leukemic blasts was also validated by this study. 
  
Future directions 
 The ultimate goals of this study are to bring targeted T-ALL therapies to the clinic 
which improve on current treatment regimens in the form of improved T-ALL survival 
rates with a simultaneous reduction in detrimental side-effects. In order to reach these 
important goals, several additional steps need to be taken first. While a great deal of 
molecular characterization work has already been done, further work must still be done in 
order to optimize LDK’s activity. Furthermore, additional animal studies in mammalian 
models must be conducted before a Phase I clinical trial can be authorized. 
 Up to this point, molecular characterization of LDK’s mechanism(s) of action has 




cycle arrest. Completion of LDK’s molecular characterization will require identification 
and validation of LDK’s direct biochemical target(s). Through pull-down experiments 
using biotinylated LDK, at least two putative molecular targets have been identified, 
IGF1-R and a second additional target that is currently deemed to be classified 
proprietary information and therefore will not be discussed in this document at this time. 
 Identification of LDK’s direct molecular targets is essential to the process of 
optimizing LDK’s therapeutic activity. Through three-dimensional modeling in silico, 
putative binding sites for LDK on its molecular targets can be identified. From this 
information, effective modifications can be proposed for LDK’s chemical structure with 
the intent of increasing its specificity, potency, or preferably both. LDK currently shows 
an IC50 of ~1 μM in Jurkat cells, whereas a good drug’s IC50 is typically considered to be 
in the nanomolar range (David Bearss, personal communication). Therefore, additional 
structure-activity relations (SAR) work needs to be done with the LDK molecule. 
 Additional work can also be done to further characterize LDK’s potential for 
treating leukemia in combination therapy with other therapeutic drugs. In this study, LDK 
slowed progression of human T-ALL in a mouse xenograft model, and one zebrafish 
model of T-ALL, rag2:c-Myc-ER, showed an excellent long-term remission response to 
LDK treatment. However, results for LDK treatment of other zebrafish T-ALL models 
developed in our lab, including Shrek, Oscar the Grouch, and Hulk, did not show the 
same degree of efficacy (K. Frazer, pers. communication). It is possible that these three 
LDK-resistant lines may use different or additional biochemical pathways for T-ALL 




may be effective in treating these leukemias in combination with other drugs that target 
the relevant effector pathways. 
 Although not the primary focus of this study, LDK has also shown some efficacy 
in treating at least some epithelial cancer cell lines, including lung, breast, ovarian, and 
prostate cancer as well as Ewing sarcoma (Trede lab, unpublished data). Although LDK 
exhibits particular specificity for hematological malignancies, this does not rule out the 
possibility that it may be useful in treating other epithelial cancers as well. The P/A/mT 
pathway is found to be up-regulated in ~50% of all cancers, and is a common mechanism 
of chemo- and radiation resistance encountered in the clinic.
7
 Thus, a novel therapeutic 
that down-regulates this pathway may have the potential to be very useful in treating both 
hematological and epithelial malignancies, either as monotherapy or in combination with 
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 The primary purpose of this thesis project was to first utilize a zebrafish drug 
screen to identify novel small molecule compound(s) with the potential to treat human T-
ALL effectively. Once identified in zebrafish, the second goal was to characterize the 
molecular mechanism of action responsible for the drugs’ observed efficacy in treating 
human T-ALL and possibly other types of cancer as well. During the course of this 
project, many experiments were performed which could not be included in the published 
Blood article (see Chapter 4), but were still relevant to the fulfillment of the primary 
research aims. 
 The purpose of this Supplementary Data Appendix is to present these additional 
unpublished experiments with their results as they relate to the goals of the thesis project. 
These supplementary experiments fall into two general categories: (1) Characterization of 
LDK’s molecular mechanism of action in treating T-ALL (Figures A.1 - A.6), and (2) 
Identification of other solid cancer types which also show sensitivity to LDK along with 
some characterization of the molecular mechanisms(s) of action responsible for the 
observed effects of LDK in these other solid cancer types (Figures A.7 - A.8).  
  
185 
Experimental results and conclusions 
  
LDK impact on AKT downstream phosphorylation target GSK-3β 
 This experiment demonstrates that LDK treatment of Jurkat T-ALL results in 
decreased phosphorylation of GSK-3β, which is a direct downstream phosphorylation 
target of AKT kinase. The effect seems to be maximized at 3.2µM. Hence, LDK appears 
to down-regulate function of the AKT pathway and possibly downstream pathways 
controlled by GSK-3β, such as glucose metabolism and Wnt signaling (Figure A.1). 
  
LDK impact on AKT downstream phosphorylation target p-BAD 
 The results of this experiment are partially unexpected. The constitutively active 
double-phosphomimetic AKT-DD construct is expected to be more active than wild-type 
AKT. Hence, expression of AKT-DD would be expected to elicit hyper-phosphorylation 
of AKT’s downstream phosphorylation target BAD. However, expression of AKT-DD 
was inversely correlated with phosphorylation of BAD in this experiment. The reason for 
this observation is unknown. We speculate that the double phosphomimetic AKT 
possibly lacks the specific tertiary conformation required for efficient phosphorylation of 
BAD. However, within each cell line, the results are as expected with LDK treatment 
resulting in down-regulation of phospho-BAD in comparison to DMSO-treated controls 
(Figure A.2). 
  
Constitutively active mTOR partially rescues LDK-treated Jurkat T-ALL 
 In this experiment, transduction of adenoviral mTOR into Jurkat cells rendered 
them partially resistant to LDK treatment. As expected, constitutively active mTOR (CA) 
had a more profound rescue effect than did wild type mTOR (WT). This experiment 
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demonstrates that down-regulation of mTOR activity in Jurkat T-ALL is responsible for 
at least some of LDK’s lethality. However, since the rescue was only partial, other effects 
of LDK may also be involved in its mechanism of action. This explains why merely over-
expressing mTOR in LDK-treated cells is insufficient for rescue (Figure A.3). 
  
Characteristics of Jurkat LDK-resistant cell line derivatives Res 3 and Res 6 
 In this experiment, Jurkat cells were deliberately conditioned to be LDK-resistant 
via constant incubation in gradually increasing concentrations of LDK over several cell 
passages. Once resistant cell lines were generated, the P/A/mT pathway was assayed for 
LDK treatment effects in parental Jurkat versus LDK-resistant Jurkat lines. The results 
show highly similar effects on phosphorylation of the Thr308 residue of AKT 
(phosphorylated by PDK1) among the three cell lines assayed. However, there is a 
marked difference among the cell lines in phosphorylation status of the Ser473 residue of 
AKT, which is phosphorylated by mTOR(C2).  The two LDK-resistant lines tested show 
a marked increase in baseline p-S473AKT status with continuing presence of p-
S473AKT even with LDK treatment. In correlation with the results shown in the 
experiment depicted in Figure A.3, this experiment also indicates that down-regulation of 
mTOR activity may be essential for LDK-mediated toxicity in Jurkat cells (Figure A.4). 
  
Spatiotemporal isolation of phospho-Aurora B kinase in HeLa cells 
 The purpose for this experiment was to further narrow down the specific mitotic 
timing of the observed G2/M delay in LDK-treated cells. Aurora B kinase is known to 
regulate abscission, which is the last checkpoint in the cell division process before 
separation of the two daughter cells. Immunostaining was employed in order to ascertain 
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both temporal and spatial distribution of p-Aur B in the treated versus control cells. HeLa 
cells were utilized because they are adherent and therefore more amenable to 
immunostaining than Jurkat cells. Furthermore, HeLa cells, though not LDK-sensitive,  
display a G2/M delay upon LDK treatment, similar to that observed in Jurkat cells.  
 These results were unexpected based on earlier observations in LDK-treated 
Jurkat cells. The number of HeLa cells displaying “midbody” p-Aur B, which is the form 
observed at the abscission checkpoint, was only ~50% of the number observed in 
untreated control cells. Furthermore, the number of p-Aur B-positive cells observed in 
metaphase was twice that counted in control cells. Moreover, the fact that half of the p-
Aur B positive metaphase cells had no organized spindle structure suggests that LDK 
may be interfering with assembly of the mitotic spindle in HeLa cells.  
Both Jurkat and HeLa cells show G2/M delay upon treatment with LDK. 
However, these data indicate that LDK may elicit a different impact on the G2/M 
transition in HeLa cells than what it does in Jurkat T-ALL. In Jurkat T-ALL, the timing 
of the G2/M delay has been isolated to occurring after metaphase but before cytokinesis 
(See Figure 4.4). By contrast, these observations in HeLa cells indicate an earlier LDK-
mediated G2/M delay centered around (pro-)metaphase when the mitotic spindle is 
forming. The difference in the observed timing of the LDK-mediated G2/M delay may be 
at least partially responsible for the difference in sensitivity to LDK treatment between 
these two cell lines (Figure A.5). 
   
LDK treatment results in increased autophagy in Jurkat cells 
The purpose of this experiment was to determine whether autophagy might be 
playing a role in LDK-mediated toxicity in Jurkat cells. Indeed, the relative amount of 
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cleaved LC3-II (14KDa) in LDK-treated cells appears to increase at the 4, 6, and 8 hour 
timepoints. However, given that the relative increase does not rise above 1.5, it is 
unlikely that autophagy has a major role in LDK-mediated toxicity. It is also unknown 
whether or not the observed increase in cleaved LC3 is a bystander or a direct effect of 
LDK treatment (Figure A.6). 
 
Ewing Sarcoma is LDK-sensitive and shows G2/M delay upon LDK treatment 
 Ewing sarcoma cell lines A673 and TC71 have consistently shown moderate 
sensitivity to LDK treatment with IC50s of ~1µM and 3µM, respectively. The purpose of 
this set of experiments was to characterize the mechanism of LDK-mediated lethality in 
Ewing sarcoma. Both cell lines tested demonstrated G2/M delay upon LDK treatment, 
similar to that observed in Jurkat cells. However, unlike Jurkat cells, neither cell line 
showed down-regulation of p-AKT(S473) upon LDK treatment, as demonstrated by 
phos-flow analysis. These results indicated that down-regulation of the P/A/mT pathway, 
and specifically mTOR(C2), may not play a significant role in Ewing Sarcoma’s 
sensitivity to LDK treatment. Rather, the G2/M delay may play a far more significant role 
in LDK’s effect on this particular cancer cell type (Figure A.7). 
  
MCF7 breast cancer derivatives Msp-Ron and sfRon are LDK-sensitive 
 MCF7 is a typical ER+ breast cancer cell line and, like Ewing Sarcoma, has 
exhibited consistent moderate sensitivity to LDK treatment with an IC50 of 2.3µM, as 
determined in the NCI60 assessment. This set of experiments was done using two 
derivatives of parental MCF7s. MCF7-Msp-Ron has been transduced with a cell surface 
receptor/intracellular signaling domain protein (Msp-Ron) which requires activation via 
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docking of the Msp ligand with the Msp receptor for activation of the Ron intracellular 
signaling domain. MCF7-sfRon, by contrast, has been transduced with a constitutively 
active form of the Ron signaling domain that is not dependent on Msp ligand docking for 
activation.  
MCF7-Msp-Ron is slightly more sensitive to LDK treatment than is MCF7-sfRon 
and shows no phosphorylation of AKT at baseline control. By contrast, MCF7-sfRon 
does show AKT activation at baseline, indicative of the constitutively active nature of the 
sfRon construct. This difference in baseline AKT activation may explain at least in part 
the observed difference in LDK sensitivity between the two cell lines. Unlike Jurkat cells, 
MCF7-sfRon exhibits S-phase delay upon LDK treatment (panel C), suggesting that LDK 
may interfere with DNA synthesis in this cell line, which interference may be 
contributory to LDK-mediated toxicity in MCF7-sfRon cells and in all MCF7 cells in 




The purposes of the experiments presented in this section were to further 
characterize LDK’s mechanism of action in sensitive cells and to expand on identifying 
additional cancer cell types besides leukemia that may show sensitivity to LDK 
treatment, as well as the relevant mechanism(s) involved. The results indicate that LDK 
likely functions via multiple non-exclusive mechanisms of action, including down-
regulation of the P/A/mT pathway, S-phase delay, G2/M delay, and possibly autophagy. 
The results vary among cell types and cell lines, suggesting that the mechanism of action 
most critical can vary depending on the cell type tested. The results also suggest that 
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epithelial cancers may also exhibit sensitivity to LDK via the same or different 
































Figure A.1. LDK impact on AKT downstream phosphorylation target GSK-3β. 
Jurkat cells were treated with either DMSO vehicle or the indicated concentration of 
LDK for 12 hours then probed for phosphorylation of GSK-3β. De-phosphorylation is 
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Figure A.2. LDK impact on AKT downstream phosphorylation target p-BAD. 
Parental Jurkat cells and Jurkat cells transduced with a doxycycline-inducible and 
constitutively active form of AKT (AKT-DD-6xHIS tag) were incubated for 12 hours 
with the indicated inhibitors at the indicated concentrations. Jurkat(AKT-DD) was tested 
both with and without 24 hour preincubation with doxycycline activation. 
Phosphorylation of BAD was then probed via Western blot. Within each cell line, LDK 
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Figure A.3. Constitutively active mTOR partially rescues LDK-treated Jurkat T-
ALL. Jurkat T-ALL was transduced with adenoviral mTOR constructs, including wild-
type (WT), kinase-dead (KD) and constitutively active (CA). Transduced cells were then 
treated with 10µM LDK for 48 hours and relative viability was assessed via MTT assay. 
WT mTOR elicited weak rescue (~33% vs 20%) while CA mTOR elicited a moderate 
rescue (~50% vs 20%) compared to either untransduced cells (“none”) or cells transduced 






















































Comparison of AKT Response in C3 
Sensitive & Resistant T-ALL lines
C-3 resistant Jurkat cell lines were created by continuous incubation in 
compound-3 over multiple cell passages. 
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Figure A.4. Characteristics of Jurkat LDK-resistant cell line derivatives Res 3 and 
Res 6. LDK-resistant Jurkat cell lines were created via continuous incubation of parental 
Jurkat T-ALL cells in LDK over multiple cell passages. (A) Resistant lines 3 and 6 
showed the highest viability and best resistance to 10µM LDK treatment as determined 
by MTT assay. (B) LDK-resistant lines Res 3 sand Res 6 show down-regulation of p-
AKT(Thr308) upon LDK treatment comparable to that of parental Jurkat cells. P-
AKT(Ser473) is strongly up-regulated in the LDK-resistant lines compared to parental 






Does LDK treatment stabilize p-Aurora 
B kinase and delay abscission?
-FACS counting of p-Aurora B in treated cells is in progress…
-Manual counting of p-Aurora B in HeLa cells indicates that: 
Cytoplasmic p-Aurora B cells are ~2.5X more in LDK-treated
Midbody structures w/p-Aurora B are ~2x fewer in LDK-treated
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Figure A.5. Spatiotemporal isolation of phospho-Aurora B kinase in HeLa cells. 
Most LDK-sensitive cell lines tested to date, including both suspension and adherent cell 
lines, have exhibited G2/M block upon LDK treatment. Assessment of cyclin A, cyclin 
B1, and phospho-histone H3 (pH3) expression patterns in LDK-treated cells indicates 
that the G2/M block occurs after metaphase (see Figure 4.4 in Chapter 4).  (A) 
Assessment of phospho-Aurora B kinase (p-Aur B) midbody expression patterns 
indicates that the G2/M block occurs after metaphase but before cytokinesis. (B) 
Immunostaining for p-Aur B kinase in HeLa cells shows that in LDK-treated cells, 
approximately twice as many are positive for diffuse p-Aur B compared to vehicle-
treated cells. Of these LDK-treated p-Aur B positive cells, approximately half (C) lack 
any obvious organized spindle structure while (A) all observed vehicle-treated p-Aur B 
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Figure A.6. LDK treatment results in increased autophagy in Jurkat cells. To 
determine whether LDK treatment increases autophagy in Jurkat cells, Jurkat cells were 
probed for cleaved LC3 on a western blot as a marker of autophagy. The cleaved form of 
LC3, LC3-II (14KDa), indicative of autophagy, increases (red box) in comparison to full-
length cytosolic LC3-I (16KDa) with LDK treatment. (Dexamethasone + Rapamycin = 
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Figure A.7. Ewing Sarcoma is LDK-sensitive and shows G2/M delay upon LDK 
treatment. (A) IC50 dose response for LDK treatment of Ewing sarcoma cell lines A673 
and TC71 which show IC50s of ~1µM and ~3µM, respectively. (Error bars = St.Dev.). 
(B-C) LDK treatment cell cycle and AKT effects in Ewing sarcoma. Upper panels - Both 
A673 and TC71 show G2/M delay upon LDK treatment. Lower panels - Despite LDK 
sensitivity, neither cell line shows a change in quantified p-AKT(Ser473) with LDK 
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Figure A.8. MCF7 breast cancer derivatives Msp-Ron and sfRon are LDK-sensitive. 
(A) LDK dose-response determination for MCF7-Msp-Ron and MCF7-sfRon. Both cell 
lines show LDK IC50s of ~10µM. (B) Western blot determination of p-AKT (Thr308 and 
Ser473) in LDK-treated MCF7-derived cell lines. MCF7-sfRON shows auto-activation of 
the AKT pathway which is down-regulated by 12 hours LDK treatment @ 10µM. Actin 
and pan-AKT = loading controls. (C) MCF7-sfRON shows S-phase cell cycle delay upon 
10µM LDK treatment for 48 hours.
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